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 ABSTRACT 
The long-term goals and objectives of our group are to identify bioactive 
natural products relevant to human disease prevention and health promotion. 
To attain this goal, the objective of this thesis was to demonstrate that 
bioactive polyphenol-rich extracts exert positive health benefits beyond basic 
nutrition, thus impacting overall health and wellness. We believe that this 
project has immense scientific merit from a human health perspective and will 
be of great public impact given that consumers are seeking natural and 
organic choices for improving health. In this investigation, we have focused 
our attention on investigating the biological activities of two novel phenolic-rich 
preparations derived from curcumin and maple syrup for future nutraceutical 
applications. 
The work herein assessed the anti-inflammatory properties of novel 
standardized curcumin formulation (Longvida®) and phenolic-enriched maple 
syrup extract using a well-known in vitro model of inflammation, 
lipopolysaccharide (LPS)-induced RAW 264.7 murine macrophages. RAW 
264.7 cells were co-treated with 50 ng/mL LPS and test extracts for 24 hours 
and then inflammatory markers were measured using gene and protein 
expression. The activation of nuclear factor-kappa B (NFκB) was measured 
using luciferase activity. Both polyphenolic extracts were able to inhibit the 
LPS stimulated inflammation by down-regulating the inflammatory markers via 
targeting nuclear factor-kappa B (NFκB) (a major pathway modulated in 
inflammation) transcriptional activity in murine macrophages.  
 Next, the work herein studied the anti-hyperglycemic and anti-lipogenic 
properties of novel standardized nutraceutical grade phenolic rich extract, 
(MSX). Human HepG2 hepatoma cells were treated with MSX for 24 h. 
Glucose consumption, AMP activated protein kinase (AMPK) activation and its 
target gluconeogenic gene expression were measured. The glucose levels 
were reduced by MSX in the hepatocytes though AMPK activation. 
Subsequently, the anti-lipogenic effect of MSX treatment in mature 
differentiated 3T3-L1 murine adipocytes and human visceral adipocytes was 
evaluated. MSX treatment to mature adipocytes decreased lipid accumulation, 
compared to control, in both murine and human adipocytes.  In 3T3-L1 
adipocytes, this effect was associated with downregulation of adipo/lipogenic 
protein expression (e.g. PPARγ, Srebp1c). We also observed reduced mRNA 
expression of the pro-inflammatory mediators, namely IL-6, and TNF-α.  
Taken together, we demonstrated that a novel maple syrup extract exhibited 
anti-inflammatory, anti-hyperglycemic and anti-lipogenic activities in vitro. 
The current study adds to the growing body of in vitro and in vivo data 
supporting the biological effects and potential health benefits of the novel 
curcumin formulation Longvida® and the natural sweetener, maple syrup. 
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PREFACE 
 
The following dissertation titled “Evaluation of in vitro anti-inflammatory, anti-
diabetic and anti-lipogenic activity of natural polyphenolic extracts and their 
pure constituents” is presented in manuscript format. There are three 
manuscripts in this dissertation. First chapter is introductory and serves as a 
general background for manuscript one, two and three. Manuscript one is 
formatted in Journal of Medicinal Food (J Med Food) journal style, second 
manuscript is in Journal of Functional Foods (J Funct Foods) style, and the 
third is in The Journal of the Federation of American Societies for 
Experimental Biology (FASEB J.) format. Manuscripts one and two are 
published in peer-reviewed journals as of March 2015. 
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1 
Introduction   
 
The rapid growth of health foods, also known as nutraceuticals, has 
immensely impacted consumers. Though variety of oral drug formulations is 
available, there is an increasing trend towards using nutraceuticals for 
prevention of diseases or as adjuncts to conventional therapies (1). Botanical 
extracts, produced from medicinal plants and plant foods, are widely 
consumed worldwide as dietary supplements for the promotion and 
maintenance of human health. Herbal natural products constitute a major 
approach of Complementary and Alternative Medicine (CAM) that is widely 
utilized by consumers. Recently, market statistics show the growing attention 
and confidence that consumers place in the herbal dietary supplements. In 
2013 alone, herbal dietary supplements sales were increased by 7.9%, and 
reported a sales figure of six billion dollars for the herb market. The 20 top-
selling herbal supplements in the natural and health foods channel in the 
United States includes turmeric, flax seed/oil, wheat or barley grass and 
cranberry etc. (2). These natural products are typically ‘whole extracts’ 
constituting complex mixtures of multiple substances found within the plant 
rather than a single compound alone.  This has arisen out of a basic 
underpinning of the biological effects of botanical extracts, namely, ‘the sum of 
the whole is greater than its parts’ due to synergy, additivity and/or 
complementary effects among multiple constituents.  
	  
 
2 
A growing body of research suggests that plant natural products, both in 
purified or extract forms, have anti-inflammatory properties and may impart 
beneficial effects against diseases with an inflammatory component (3-6). 
Dietary intake of bioactive class of compounds ‘phenolics’ with antioxidant and 
anti-inflammatory properties represents one mechanism to combat 
inflammation and promote overall human health. Polyphenols play a 
significant role in human nutrition and health, as these potent bioactive 
constituents are the most abundant phytochemicals in our diet (7-10). Possible 
efficacy of phenolics including biological extracts such as grape seed extracts, 
cocoa extracts, etc or pure constituents like resveratrol, curcumin. on 
inflammation, glucose and lipid homeostasis has been well published in cell 
culture studies, animal models and some clinical trials (14,11-13) 
It is now well accepted that inflammation and associated pro-inflammatory 
processes are centrally linked to several chronic human diseases including 
cancer, diabetes, cardiovascular and neurodegenerative diseases (15-17). 
Regulatory mechanisms that monitor metabolism and immunity overlap with 
each other at many stages (18). The factors contributing to metabolic diseases 
like diabetes and obesity are insulin resistance, impaired glucose and lipid 
metabolism (19). As stated earlier, along with chronic inflammation, altered 
balance of pro-inflammatory and inflammatory factors are also involved in the 
pathogenesis of these metabolic diseases. Multiple complex molecular 
pathways that involve JNK, NFκB, SOCS, AMPK and PPAR family members 
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are responsible for development of hepatic insulin resistance by inflammation 
(18).  
The Nuclear factor kappa B (NFκB) signaling pathway has been well 
characterized and is considered to be a predominant signaling pathway in 
inflammation (15, 16). The activated form of NFκB has been reported to be 
involved in chronic inflammatory diseases such as cancer, atherosclerosis, 
myocardial infarction, diabetes, arthritis, Alzheimer’s disease, osteoporosis, 
and other (20-22). Thus, agents that can suppress NFκB activation, such as 
plant natural products can potentially prevent, delay the onset, or treat NFκB -
linked diseases (23-25). Moreover, many well-known antioxidants that are 
currently being marketed in nutraceutical preparations, such as resveratrol, 
curcumin, and pomegranate, are thought to elicit anti-inflammatory effects 
through downregulation of the NFκB signaling pathway in macrophages (26, 
27). Hence, in manuscript two and three we have demonstrated the anti-
inflammatory activities of standardized curcumin formulation Longvida® and 
polyphenolic maple syrup extract in RAW 264.7 macrophage model. 
In the first manuscript, ‘Anti-inflammatory effects of novel standardized 
solid lipid curcumin formulations’, we have investigated in vitro biological 
effects of Longvida®, a commercially available standardized novel curcumin 
formulation, on the NFκB signaling pathway which is a major molecular 
pathway involved in inflammation (15, 16). The investigations carried out in 
last few decades, confirmed that curcumin (the most active constituent of the 
curry spice turmeric) targets many transcription factors (NFκB, ATF3, AP-1, 
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STAT-3), inflammatory mediators (NO, PGE2, cytokines), enzymes, growth 
factors, protein kinases and cell-cycle regulatory proteins (27-30). Despite the 
promising health benefits of curcumin, water insolubility, low bioavailability and 
poor absorption are the limiting factors for the use of curcumin as a potential 
preventive and therapeutic agent (29, 31). Lately, very promising results were 
observed in an in vivo single-dose pharmacokinetic study of standardized 
novel solid lipid curcumin particle (SLCP) preparation (Longvida®), which 
reported 65 fold increased bioavailability of the preparation relative to generic 
curcumin extract and suggests the potential for sustained release dosage form 
(32). Furthermore an acute and subchronic toxicity study in rats and mice 
demonstrated the safety of SLCP and the No Observed-Adverse-Effect Level 
(NOAEL) was determined to be 720 mg/kg bw/day, the highest dose tested 
(33). Moreover, a recent study demonstrated that a low dose of a Longvida® 
(80 mg/ day) can produce a variety of potentially health promoting effects in 
healthy middle-aged people (34). Yet the effects of this bioavailable curcumin 
preparation Longvida® on inflammation remains unknown and detail 
investigation is needed. Thus, in the first manuscript we focused our attention 
on evaluating anti-inflammatory effects of this novel nutraceutical formulation 
Longvida®.  
In the second manuscript, ‘Phenolic mediated anti-inflammatory properties 
of a maple syrup extract in Raw 264.7 murine macrophages’, we 
demonstrated that maple syrup extract attenuated lipopolysaccharide induced 
inflammation via NFκB pathway in the same murine macrophage model that 
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was used in manuscript 1. Herein we have also investigated anti-inflammatory 
activities of fifteen pure compounds isolated from maple syrup extract. Maple 
syrup is a widely consumed natural sweetener with well-studied chemistry. 
Canada and eastern North America are chiefly responsible for the major 
commercial production of available maple syrup. Being the world’s largest 
maple syrup supplier, this industry plays a critical role in the economy of this 
region. Maple syrup is a very interesting food to investigate, primarily due to its 
unique chemical profile. This natural sweetener constitutes mainly of 
carbohydrates (sucrose) along with various nutrients such as minerals, 
vitamins, amino acids, organic acids, phytohormones (abscisic acid, phaseic 
acid and their metabolites) and most importantly various phytochemicals 
(majorly phenolics belonging to the sub-classes lignan, phenolic acid, stilbene, 
coumarin, and flavonoid). The chemistry of maple syrup has been extensively 
studied; however there are very few biological studies that have been 
conducted. Thus, in this study we investigated the mechanistic insights into 
the anti-inflammatory activity of maple syrup extract and it’s pure constituents. 
We believe that accomplishing this project has lead to increased scientific 
knowledge on the ‘matrix’ effects of multiple constituents exerting positive 
biological effects to this sweetener beyond sucrose alone. This project is thus 
necessary along the research continuum on this natural product. 
Our maple syrup research has lead to the development of the first 
nutraceutical grade botanical extract from this food (named MSX) (35). Initially, 
the laboratory scale maple syrup extract project was focused on inflammatory 
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pathways but gradually it evolved, and then we started exploring the 
mechanisms involved in metabolic diseases like diabetes, obesity etc. that has 
chronic inflammatory component using food grade extract MSX. In the third 
manuscript titled, ‘In vitro hypoglycemic and lipid lowering effects of a 
standardized food grade maple syrup extract (MSX)’, we have explored 
glucose lowering and lipid lowering potential of a nutraceutical grade MSX 
extract using hepatocytes and adipocytes respectively.  
Searching for a signaling mechanism for the hypoglycemic action of MSX 
extract, we have explored its effect on 5' adenosine monophosphate-activated 
protein kinase (AMPK) activation in human HepG2 hepatoma cell model. 
AMPK, a heterotrimeric serine/threonine kinase, is a vital metabolic regulator 
of fatty acid and glucose homeostasis. It is emerging as a potential target for 
the treatment of diabetes and chronic inflammatory diseases (19). Numerous 
studies have reported that the activation of AMPK can inhibit NFκB signaling 
indirectly, a master regulator of inflammation, both in vitro and in vivo (36). 
Recently, activation of AMPK by metformin, a first-line anti-diabetic drug, has 
been shown to decrease glucose production and increase fatty acid oxidation 
in the liver (37, 38). It has been reported that AMPK activation by polyphenols 
may be at least partially responsible for their therapeutic benefits on 
hyperlipidemia in diabetes (39).  
Moreover, there is a strong interplay between inflammation, diabetes and 
obesity. Adipocyte dysfunction has been linked to the development of type 2 
diabetes, insulin resistance along with sub-clinical inflammation. Polyphenolic 
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compounds such as catechins, resveratrol etc. have modulatory effects on 
many complex pathways in adipose tissue including upregulation of fatty acid 
oxidation and reduction in the expression of the transcription factors, enzymes 
and genes involved in lipogenesis e.g. peroxisome proliferator-activated 
receptor γ (PPARγ), CCAAT enhancer-binding protein-α (C/EBP-α), Sterol-
regulatory element-binding protein 1-c (Srebp-1c), fatty acid binding protein 
(FABP4), fatty acid synthase (FAS), and perillipin, etc. (14). A natural 
polyphenol, resveratrol has been shown to attenuate adipogenesis and 
lipogenesis in both murine and human adipocytes including mature and 
differentiating adipocytes cell models. Resveratrol has been used in several 
clinical trials and exhibited its effectiveness in inflammatory conditions and 
metabolic diseases. Thus, in this third manuscript, we investigated MSX 
effects on lipogenic pathways and adipo/lipogenic transcription factors in 
mature murine and human adipocytes. This study has provided data that will 
support the design of future preclinical trials with maple bioactives. 
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1.1. Abstract  
Inflammation and the presence of pro-inflammatory cytokines are associated 
with numerous chronic diseases such as type-2 diabetes mellitus, 
cardiovascular disease, Alzheimer's disease, and cancer. An overwhelming 
amount of data indicates that curcumin, a polyphenol obtained from the Indian 
spice turmeric, Curcuma longa, is a potential chemopreventive agent for 
treating certain cancers and other chronic inflammatory diseases. However, 
the low bioavailability of curcumin, partly due to its low solubility and stability in 
the digestive tract, limits its therapeutic applications. Recent studies have 
demonstrated increased bioavailability and health promoting effects of a novel 
solid lipid particle formulation of curcumin (Curcumin SLCP, Longvida®).  The 
goal of the current study was to evaluate the aqueous solubility and in vitro 
anti-inflammatory effects of SLCP formulations using lipopolysaccharide 
(LPS)-stimulated RAW 264.7 cultured murine macrophages. SLCPs treatment 
significantly decreased nitric oxide (NO) and prostaglandin-E2 (PGE2) levels at 
concentrations ranging from 10-50 µg/mL, and reduced Interleukin-6 (IL-6) 
levels in a concentration-dependent manner. Transient transfection 
experiments using a nuclear factor-kappa B (NF-κB) reporter construct 
indicates that SLCPs significantly inhibit the transcriptional activity of NF-κB in 
macrophages. Taken together, these results show that in RAW 264.7 murine 
macrophages, SLCPs have improved solubility over unformulated curcumin, 
and significantly decrease the LPS-induced pro-inflammatory mediators NO, 
PGE2 and IL-6 by inhibiting the activation of NF-κB. 
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Tumor necrosis factor-α (TNF-α). 
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1.2. Introduction 
Inflammation and associated pro-inflammatory processes are centrally linked 
to several chronic human diseases including cancer, diabetes, obesity, 
arthritis, cardiovascular and neurodegenerative diseases1-6. During 
inflammation, macrophages play a critical role in managing various 
immunopathological phenomena, including the overproduction of inflammatory 
markers such as nitric oxide (NO), prostaglandin-E2 (PGE2), tumor necrotic 
factor α (TNFα) and cytokines like interleukin-6 (IL-6) and interleukin-1β (IL-
1β).  A number of inflammatory stimuli, for e.g. lipopolysaccharides (LPS) and 
pro-inflammatory cytokines, activate immune cells to produce inflammatory 
mediators, and these are therefore useful targets in the development of novel 
anti-inflammatory drugs and in the evaluation of the molecular mechanisms of 
potential anti-inflammatory drugs7, 8. Thus, dietary agents that can suppress 
inflammatory markers, such as plant natural products, can potentially prevent, 
delay the onset, and/or treat inflammation and inflammatory-mediated 
diseases. A growing body of research suggests that plant phenolic compounds 
which possess antioxidant and anti-inflammatory properties offer an attractive 
dietary strategy to combat inflammation and promote human health and 
wellness 9, 10. 
Curcumin (diferuloylmethane) is derived from the ground rhizomes of 
the Curcuma longa L. plant and is the most active curcuminoid in the Indian 
curry spice, turmeric11, 12. Curcumin is a lipophilic, water insoluble, low 
molecular weight polyphenol (MW = 368 g/moL), which has been used for 
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culinary applications in many parts of the world. In Ayurveda, turmeric is 
widely used to treat a variety of conditions ranging from acute infections, 
wounds, and injuries in addition to chronic diseases like diabetes, asthma, and 
various inflammatory diseases13-15. A vast number of published research 
studies support a wide range of pharmacological effects of curcumin including 
anti-oxidant, anti-cancer, anti-Alzheimer’s disease and anti-inflammatory 
effects both in vitro and in vivo 13, 16. On a molecular level, curcumin targets 
many transcription factors (including NF-κB, AP-1, STAT-3), inflammatory 
mediators (PGE2, cytokines), enzymes, growth factors, protein kinases and 
cell-cycle regulatory proteins 13, 17-19 
 Despite the promising health benefits of curcumin, its low water solubility 
limits its oral delivery in aqueous-based formulations which are popular among 
consumers and widely used in the nutraceutical and functional food industries.  
Moreover, the  poor bioavailability and extensive phase-II metabolism of 
curcumin are limiting factors for the oral dosage of unformulated curcumin 
which limits its potential as a preventive and/or therapeutic agent19, 20. Various 
Clinical trials have reported low systemic bioavailability of curcumin even after 
oral administration of doses up to 12 g/kg/day 16, 21. Several research 
strategies have been undertaken to improve the bioavailability of curcumin, 
including blocking non-specific metabolic pathways, as well as novel drug 
delivery systems and formulations like liposomes, nanoparticles and 
phospholipid complexes 13, 22. In a clinical study, a combination of curcumin 
and piperine, a nonspecific CYP-450 and (UDP-glucuronosyltransferase) UGT 
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inhibitor, resulted in increased curcumin bioavailability, but with an absorption 
half-life of only 7 minutes 23. Other in vitro studies suggest that polymer-based 
nanoparticle formulations of curcumin, also known as ‘nano-curcumin’, exhibit 
pharmacological activity at slightly lower concentrations than that of pure 
curcumin in human pancreatic cancer cell lines 24. However, the potential 
increase in bioavailability of these latter formulations is offset by the lack of 
data and clinical trials on the safety and metabolism of nanoparticle 
formulations in humans. 
 Recently, a single-dose human pharmacokinetic study of a standardized 
novel solid lipid curcumin particle (SLCP) preparation (commercially available 
as Longvida®) reported increased bioavailability compared to a generic 
curcumin extract, suggesting the potential for sustained release dosage forms 
of this natural product25. Moreover, acute and sub-chronic animal toxicity 
studies by Dadhaniya et al. (2011) demonstrated the safety of the SLCP and 
the No Observed-Adverse-Effect Level (NOAEL) was determined to be 720 
mg/kg bw/day which was the highest test dose26. In addition, DiSilvestro et al. 
(2012) demonstrated that a low dose of a Longvida® (80 mg/day) imparted 
potentially health promoting effects in healthy middle-aged humans27. Also, in 
a recent investigation, Longvida® selectively suppressed soluble Tau dimers 
and corrected molecular chaperone, synaptic, and behavioral deficits in 
transgenic mice suggesting that this curcumin formulation may have potential 
beneficial effects against Alzheimer’s disease28. However, to date, the effects 
of this bioavailable curcumin preparation, namely, Longvida®, on inflammation 
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and inflammatory biomarkers remains unknown. 
 The goal of the present study was to evaluate the effects of two novel 
SLCP preparations using LPS-stimulated RAW 264.7 macrophages, a well-
established in vitro anti-inflammatory model. LPS increases inflammatory 
markers such as NO, PGE2 and IL-6 and we hypothesized that the 
standardized SLCP formulations would block the expression of pro-
inflammatory mediators. 
 
1.3. Materials and Methods 
1.3.1. Solid Lipid Curcumin Particle (SLCP) Formulations and Curcumin 
Extract 
The solid lipid curcumin particle (SLCP) preparation (Longvida®, SLCP-1), a 
solution-dispersible SLCP preparation (Longvida® SD, SLCP-2), and a 
curcumin extract (containing 95 % curcuminoids) were provided to our 
laboratory by Verdure Sciences (Noblesville, IN, USA). The SLCP extracts 
were produced using patent-pending methodology as described previously25, 
27 and were standardized to contain approximately 20 % curcumin25, 26. SLCP-
1 is a granular powder used for tablets and capsules, and SLCP-2 is a fine 
powder intended for use in other dosage forms. Briefly, turmeric root extract 
was mixed with pure phosphatidylcholine, vegetable stearic acid, ascorbic acid 
(vitamin C) palmitate, and other inert ingredients. The formulations were 
manufactured under cGMP standards and meet internal and external 
specifications for precise chemical and physical characteristics. The solubility 
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of the two SLCP formulations and the curcumin extract are shown in Table 1 
(data provided by Verdure Sciences). 
 
1.3.2. Cell culture 
RAW 264.7 mouse macrophage cells were obtained from American Type 
Culture Collection (ATCC, Manassas, VA). RAW 264.7 cells were routinely 
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10 
% v/v fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 
µg/mL) (Sigma-Aldrich, St. Louis, MO) and maintained at 37 ºC with 5 % CO2 
humidified air. Stimulated RAW 264.7 cells (1 x 105/100 µL) were treated with 
50 ng/mL LPS (Sigma-Aldrich, St. Louis, MO) with or without different 
concentrations of test samples (10, 25, and 50 µg/mL) for 24 h.  All test 
samples were solubilized in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. 
Louis, MO) with a final DMSO concentration < 0.1% in the culture medium. 
Cell culture supernatants were collected for nitrite (NO), PGE2, and cytokine 
assays.  
 
1.3.3. Cytotoxicity Assay 
The viability of RAW 264.7 macrophages after 24 h of continuous exposure to 
the test compounds was determined by performing colorimetric MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymeth-oxyphenyl)-2-(4-sulphenyl)-2H-
tetrazolium salt] assay (Promega, Madison, CA) according to the protocol 
described previously but with minor modifications29. Briefly, after 24 h of 
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treatment, 20 µL of MTS reagent was added to each reaction well (in a 96-well 
format).  After 2 h of incubation, the absorbance was measured at 490 nm 
using a spectrophotometer (SpectraMax M2, Molecular Devices Corp, 
Sunnyvale, CA).  
 
1.3.4. Nitrite determination 
RAW 264.7 macrophages were plated in a 96-well plate (1 × 105 cells/100 µL) 
and incubated at 37 °C for 24 h. After 24 h, the medium was replaced and the 
cells were co-treated with 50 ng/mL LPS and different concentrations of the 
SLCP formulations  (10, 25 and 50 µg/mL) for 24 h at 37 °C. Cells that were 
not treated with LPS served as a negative control. After 24 h, the cell culture 
supernatants were collected and incubated (1:1, v/v) with modified Griess 
reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% 
naphthylethylenediamine dihydrochloride in distilled water) (Sigma-Aldrich, St. 
Louis, MO) for 20 min at room temperature as previously described30. The 
absorbance at 540 nm was measured using a spectrophotometer (SpectraMax 
M2, Molecular Devices Corp, Sunnyvale, CA).  The nitrite concentration was 
quantified by comparison with a sodium nitrite standard curve. The assay was 
performed in triplicate for each concentration. 
 
1.3.5. PGE2 determination 
To evaluate the effects of various concentrations of the SLCP-1 and SLCP-2 
formulations on PGE2 levels, PGE2 metabolites accumulated in the cell 
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supernatants were measured using a PGE2 enzyme-immunoassay (EIA) kit 
(Cayman Chemical, Ann Arbor, MI), according to the manufacturer’s protocol. 
The assay was performed in triplicate for each concentration. 
 
1.3.6. Determination of IL-6 
The effects of the SLCP-1 and SLCP-2 formulations on the production of pro-
inflammatory cytokine IL-6 was determined by Bio-Plex® Multiplex 
Immunoassays (BioRad Laboratories, Hercules, CA), as described by the 
manufacturer’s instructions. The experiment was performed in quadruplicate. 
 
1.3.7. Transient transfection and luciferase assay 
LPS-induced NF-κB upregulation accounts for a part of LPS-mediated 
activation of variety of inflammatory genes and hence it is important to identify 
the effects of SLCP formulations on the transcriptional activity of NF-κB 31. To 
monitor these effects of the two SLCP formulations, RAW 264.7 macrophages 
were transiently co-transfected with pNF-κB and pRL-CMV reporter vectors 
(Promega, Madison, CA) using GenePORTER® 3000 Transfection Reagent 
(Genlantis, San Diego, CA) according to the manufacturer’s protocol. Briefly, 
the cells were seeded into 96-well plates (1.2 × 104 cells/100 µL) in complete 
medium without antibiotics (DMEM +10 % FBS) and incubated for 24 h (~50-
70 % confluency). Cells were then treated with the transfection complexes and 
incubated for 72 h before treatment with each SLCP formulations (10, 25, and 
50 µg/mL) for 2 h.  LPS was added after 2 h (1 µg/mL). After 5 h, cells were 
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lysed with 20 µL passive lysis buffer and NF-κB activity was measured as 
relative firefly/renilla luciferase activity using a Dual-Luciferase® Reporter 
Assay System (Promega, Madison, CA) with a GloMaxTM 20/20 Luminometer 
(Promega, Madison, CA) according to the manufacturer’s protocol. All samples 
were tested in quadruplicate. Luciferase activity was recorded as relative light 
units (RLU) and expressed as fold change relative to LPS-treatment control 
and the assay was performed using three replicates for each concentration. 
 
1.3.8. Statistical analysis 
All statistical analyses were carried out using the software program GraphPad 
Prism Version 5.0 (GraphPad Software, La Jolla, CA). Experimental data were 
grouped by one variable and were analyzed by one-way ANOVA followed by a 
Dunnett's multiple comparison test. A value of p < 0.05 was considered 
significant. 
 
1.4. Results  
1.4.1. Aqueous solubility of SLCP formulations vs. curcumin  
The SLCP-1 and SLCP-2 formulations were both soluble in water, with SLCP-
1 possessing ca. 14 % solubility and SLCP-2 having ca. 76 % solubility (see 
Table 1).  On the other hand, the curcumin extract exhibited significantly less 
solubility in water which was in agreement with the previous data published by 
Kurien et al. (2007)32. Given this solubility data as well as the previously 
published data supporting the increased bioavailability of the SLCPs 
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compared to a generic curcumin extract in humans, 25 we proceeded to further 
evaluate the SLCP formulations in targeted in vitro bioassays (described 
below). 
 
1.4.2. Effect of SLCP formulations on LPS-induced NO production 
NO and PGE2 are secreted into cell culture supernatant by RAW 264.7 murine 
macrophages when they are treated with LPS. Since NO is highly unstable, 
the accumulation of nitrite (a stable oxidized product of NO) in culture media is 
often used as a biomarker for NO production in LPS-activated macrophages33. 
A nitric oxide assay was used to evaluate the effect of the SLCP formulations 
on NO production as described in section 2.4. RAW 264.7 cells were 
incubated with or without LPS (50 ng/mL) in the presence or absence of test 
samples (10, 25 and 50 µg/mL) for 24 h. In LPS-stimulated macrophages, 
nitrite levels increased significantly to 88.7 ± 6.2 µM as compared to the 
solvent control (Fig. 1A). In Fig. 1A, treatment with SLCP formulations 
suppressed nitrite concentration in LPS-activated macrophages in a 
concentration-dependent manner. At 25 µg/mL, both SLCP formulations 
significantly decreased medium nitrite to 33.5 ± 4.2 µM and 61.6 ± 2.0 µM 
respectively. At 50 µg/mL, SLCP-1 and SLCP-2 both inhibited LPS-induced 
NO production in macrophages by 100 %. No nitrite production could be 
detected in cells treated with test compounds without LPS (data not shown).  
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1.4.3. Effect of SLCP on PGE2 production 
We next evaluated the effects of SLCP on LPS-induced PGE2 synthesis in 
RAW 264.7 cells. The same supernatants were used for measurement of 
PGE2.  After stimulation with LPS (50 ng/mL), PGE2 was released into the 
culture medium and rapidly converted into its metabolite. As shown in Fig. 1B, 
at 10 µg/mL SLCP-1and SLCP-2 lowered LPS-induced PGE2 production to 
about 31 and 25 %, respectively. Treatment with 25 µg/mL of SLCP-1 and 
SLCP-2 significantly suppressed PGE2 levels by about 66 and 64 % 
respectively, whereas both the test compounds at 50 µg/mL concentration 
reduced PGE2 levels to about 96 % as compared to control. The SLCP 
formulations did not significantly increase PGE2 levels in cells which were not 
treated with LPS (data not shown). Thus our results show that SLCPs inhibited 
PGE2 production in a concentration-dependent manner in LPS-stimulated 
cells. The test compounds were not responsible for altering the viability of 
activated macrophages as determined by MTS assay (see Supplementary 
Fig.1).  Hence, the observed reduction in NO and PGE2 production by the 
SLCP treatments was not attributed to cytotoxic effects. 
 
1.4.4. Effects of SLCPs on the levels of IL-6 
LPS induction in macrophages causes the up-regulation of pro-inflammatory 
cytokines such as IL-6 34. Consequently, the effect of varying concentrations of 
the test compounds on this cytokine was evaluated. LPS treatment 
significantly elevated levels of IL-6 (6043 ± 589.94) in the media (Fig. 2). IL-6 
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levels in macrophages treated with the test compounds alone, without LPS, 
were negligible (data not shown). The SLCP formulations suppressed IL-6 
levels in a concentration-dependent manner. At 25 and 50 µg/mL of SLCP-1 
treatment, IL-6 levels were significantly reduced by 29.4 and 97.4 % 
respectively. Similarly, treatment with 10, 25 and 50 µg/mL of SLCP-2 
decreased IL-6 production by about 2, 13 and 95 %, respectively. This data 
suggested that, both SLCP formulations were effective in lowering IL-6 levels 
in LPS-stimulated macrophages, with SLCP-1 being slightly more effective 
than SLCP-2 at higher concentrations. 
 
1.4.5. Effects of SLCP formulations on NF-κB activation 
The activation of the transcription factor, NF-κB is a key-step in stimulating 
pro-inflammatory signals. Thus, we next investigated the effect of the SLCP 
formulations on NF-κB activity, by transient transfection of macrophages 
followed by luciferase assay. After treatment with 1 µg/mL LPS, the NF-κB 
activity of the macrophages was significantly increased as compared to control 
(Fig. 3). Treatment with the SLCPs formulations significantly reduced NF-κB 
transcription activity in a concentration dependent manner, as shown in Fig. 3. 
NF-κB luciferase activity was decreased to almost 10-fold with 10 µg/mL of 
SLCP-1 treatment, whereas with 10 µg/mL of SLCP-2, the activity was 
reduced to about 6-fold as compared to control.  
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1.5. Discussion 
Inflammation is a key component in multiple disease states35. Based on a 
review of the literature, the NF-κB signaling pathway is the predominant 
upstream molecular signaling pathway that causes inflammation through 
enhanced cytokine, nitric oxide, and prostaglandin production36. Several 
studies in different animal models and in human trials support the diverse 
pharmacological effects of curcumin including anti-proliferative, anti-
angiogenic, anti-oxidant, anti-inflammatory, anti-microbial, hepato- and 
nephro-protective properties etc.22. The SLCPs are novel proprietary curcumin 
formulations with improved solubility and bioavailability compared to generic 
curcumin. 25 In this study, we investigated the inhibitory effects of the SLCP 
treatments on the inflammatory response initiated by LPS in RAW 264.7 
macrophages.  
In inflammation, macrophages undergo sequential steps to release pro-
inflammatory mediators like cytokines, NO and PGE2. These molecules recruit 
other immune cells to the sites of inflammation. Therefore inhibition of the 
release of these chemicals is a good strategy for monitoring inflammatory 
diseases 35.  
In the current study, we reported that LPS-activated RAW 264.7 murine 
cells treated with improved-solubility curcumin formulations, namely,  SLCP-1 
and SLCP-2, exhibited concentration-dependent down regulation of NO and 
PGE2 production. These observations were in agreement with the previous 
studies, which reported the inhibition of NO through the suppression of 
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inducible, NO synthase gene and protein expression by curcumin in LPS and 
IFN-γ activated RAW 264.7 macrophages37, 38. Our study further revealed that 
the SLCP treatments on LPS-activated macrophages decreased IL-6 levels in 
a concentration dependent manner. It has been demonstrated previously that 
there is a reduction in LPS-induced IL-6 levels with curcumin treatment in 
macrophages 39, 40. Moreover, it was reported that curcumin blocked the LPS-
induced NF-κB activation through the prevention of Inhibitor κB degradation in 
RAW 264.7 cells 38.  Thus, the down regulation of NF-κB activation can be one 
of the many mechanisms underlying the anti-inflammatory effects of the 
SLCPs.  
The improved solubility of SLCP formulations compared to regular 
curcumin (see Table 1) may be due to the amphiphilic nature of SLP 
formulations that utilize phospholipids and other lipids to solubilize curcumin in 
aqueous solutions. In previous studies, similar types of formulations 
contributed to the creation of micelle type physical structures that permit 
increased dissolution of lipophilic compounds.  SLCP-1 and SLCP-2 differ with 
respect to powder size, and the differential solubility between them (Table 1) 
may be due to the relative amount of surface area exposed to the aqueous 
medium. In this study, it was found that SLCP-2 possessed greater water 
solubility than SLCP-1, likely due to its decreased powder size and thus 
increased surface area exposed to the aqueous solution. However, both 
SLCPs possessed similar activity in vitro on inflammatory mediators. Future 
research may investigate the dissolution and micellar characteristics of these 
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formulations and their interactions with cytokines on a molecular level. Overall, 
the increased aqueous solubility of the SLCP formulations compared to natural 
curcumin leads to a broader scope of possible formulations which can be 
utilized by the nutraceutical and functional food industries.   
In toto, solid lipid curcumin particle (SLCP) formulations dose-
dependently mitigated the LPS-induced inflammatory response in 
macrophages, by down regulation of the production of the inflammatory 
markers NO, PGE2 and IL-6 through inhibition of NF-κB activation. SLCP-1 
was slightly more effective at inhibiting the anti-inflammatory response than 
SLCP-2, and this may be due to concentration-dependent effects. The current 
findings suggest the use of increased-water soluble curcumin formulations 
such as SLCPs as potential therapeutic agents to combat chronic 
inflammatory diseases. Further investigations should explore the potential use 
of SLCP in the prevention and/or therapy of inflammation-linked diseases but 
future in vivo studies on SLCP are warranted to determine the clinical efficacy 
of these formulations of curcumin. 
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1.6. Figure legends 
 
Fig. 1: Effects of SLCP formulations on: a) Nitrite and b) PGE2 production 
in LPS-stimulated RAW 264.7 cells. Cells were co-treated with LPS (50 
ng/mL) and samples (10, 25, 50 µg/mL) for 24 h. SLCP-1 and SLCP-2 
inhibited NO and PGE2 levels in LPS-stimulated macrophages in a 
concentration-dependent manner. Data are expressed as mean values ± SD. 
aP < 0.001 and bP < 0.01 indicate a significant difference as compared with the 
LPS-treated group. 
 
Fig. 2: Effect of SLCP formulations on LPS-induced production of pro-
inflammatory cytokines including IL-6 in RAW 264.7 cells. The SLCP 
formulations were able to suppress IL-6 levels in a concentration dependent 
manner. Data are expressed as mean values ± SD. aP < 0.001 and cP < 0.05 
indicate a significant difference as compared with the LPS-treated group.  
 
Fig. 3: Effect of SLCP formulations on NF-κB activation in stimulated 
RAW 264.7 macrophages. The SLCP formulations significantly inhibited the 
transcriptional activity of NF-κB in LPS-activated murine macrophages at 
tested concentrations. Data are expressed as mean values ± SD. aP < 0.001 
indicate a significant difference as compared with the LPS-treated group. 
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1.7. Tables 
 
 
Table 1. Solubility of curcumin extract and the SLCP formulations in 
water. 
Test samples 
Solubility in water 
(%) 
Solubility in water 
(µg/mL) 
Fold 
improvement 
Curcumin (unformulated) 0.00006 0.6 1 
SLCP-1 (Longvida®) 14 140,000 233,000 
SLCP-2 (Longvida®) 76 760,000 1,270,000 
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1.8. Figures 
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Fig. 1: Effects of SLCP formulations on: a) Nitrite and b) PGE2 
production in LPS-stimulated RAW 264.7 cells. 
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stimulated RAW 264.7 macrophages. 
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2.1. Abstract 
The in vitro anti-inflammatory effects of a phenolic-enriched Canadian maple 
syrup ethyl acetate extract (MS-EtOAc) and 15 purified phenolic constituents 
were evaluated in a LPS-stimulated RAW 264.7 murine macrophage cell 
model. MS-EtOAc decreased nitric oxide (NO) and prostaglandin-E2 (PGE2) 
production at 10-100 µg/mL concentrations. The observed NO inhibition was a 
direct result of reduced nitric oxide synthase (iNOS) protein and gene 
expression through suppression of NF-κB transcriptional activation. In 
addition, MS-EtOAc upregulated cyclooxygenase-2 (COX-2) mRNA and 
protein expression. Among the 15 pure isolates, (E)-3,3'-dimethoxy-4,4'-
dihydroxystilbene was most effective in decreasing both NO and PGE2 levels. 
However, 4-acetylcatechol, tyrosol, and protocatechuic acid only reduced 
PGE2 levels. Thus, the potential anti-inflammatory activity of MS-EtOAc can be 
attributed to its unique combination of compounds and not as a result of a 
single purified phenolic constituent alone. Future research on the purified 
phenolic compounds will be useful in understanding the overall in vitro anti-
inflammatory effects of maple syrup.  
 
 
 
 
Keywords: Maple syrup extract; Phenolics; Inflammation; RAW 264.7 
Macrophages; Lipopolysaccharide 
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Abbreviations 
Nuclear factor kappa B (NF-κB); nitric oxide (NO); prostaglandin-E2 (PGE2); 
prostaglandins (PGs); tumor necrosis factor-α (TNF-α); interleukin-1 (IL-1); 
interleukin-6 (IL-6); cyclooxygenases (COX); nitric oxide synthase (NOS); 
cyclo-oxygensase-2 (COX-2); inducible nitric oxide synthase (iNOS); Maple 
syrup ethyl acetate extract (MS-EtOAc); lipopolysaccharide (LPS); fetal bovine 
serum (FBS); Dulbecco’s modified Eagle’s medium (DMEM); Quantitative real-
time polymerase chain reaction (qRT-PCR); enzyme-immunoassay (EIA); 
phosphate buffered saline (PBS); tris-buffered saline with Tween 20 (TBST); 
relative light units (RLU) 
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2.2. Introduction 
Functional foods and nutraceuticals, consumed for human health promotion 
and disease risk reduction, are among the fastest growing sectors of the 
modern food industry (Hardy, 2000). This has led to increased interest into the 
discovery and applications of new functional ingredients, from both marine and 
terrestrial sources, by several research laboratories (Marete, Jacquier, & 
O’Riordan, 2011; Vo & Kim, 2013). Similarly, our group has been involved in 
the identification of bioactive compounds from maple (Acer) species and 
maple syrup (Li & Seeram, 2010, 2011a, 2011b; González-Sarrías, Li, & 
Seeram, 2011; Apostolidis, Li, Lee, & Seeram, 2011).  Notably, our research 
efforts in this area have contributed, in part, to the recent commercial 
development and utilization of maple sap/water as a functional beverage 
(Yuan, Li, Zhang & Seeram, 2013; http://ilovemaple.ca/products/maple-water). 
In the current project, we have now focused our attention on investigating the 
biological activities of a ‘phenolic-enriched and sugar-reduced’ extract derived 
from maple syrup (further explained below) for future potential applications as 
a functional food ingredient.  
Maple syrup is a natural sweetener produced by concentrating the 
watery sap collected from maple species including the sugar maple (Acer 
saccharum) and red maple (Acer rubrum) species, which are both native to 
North America (Li & Seeram, 2010; Perkins & van den Berg, 2009). Maple 
syrup contains sugars (mainly as sucrose), organic acids, amino acids, 
minerals, and phytochemicals, the latter of which occur primarily as phenolics 
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(Abou-Zaid, Nozzolillo, Tonon, Coppens, & Lombardo, 2008; Ball, 2007; Li & 
Seeram, 2010). As mentioned above, our laboratory has previously isolated 
and identified more than fifty phenolics from maple syrup belonging to the 
lignan, coumarin, stilbene, and phenolic derivative sub-classes (Li & Seeram, 
2010, 2011a, 2011b).  
Published studies have shown that phenolic-enriched extracts of maple 
sap and syrup have in vitro anti-oxidant, anti-proliferative, anti-radical and anti-
mutagenic activities (Legault, Girard-Lalancette, Grenon, Dussault, & Pichette, 
2010; Theriault, Caillet, Kermasha, & Lacroix, 2006). In addition, our group 
has shown that phenolic-enriched maple syrup extracts and their purified 
constituents inhibit the growth of human colon cancer cell lines mediated by 
cell cycle arrest (González-Sarrías, Li, & Seeram, 2011).  We also reported 
that maple syrup extract inhibits the activities of α-glucosidase and α-amylase 
enzymes using in vitro models (Apostolidis, Li, Lee, & Seeram, 2011). 
However, until now, the anti-inflammatory activity and the associated 
molecular mechanisms elicited by phenolic-enriched maple syrup extract have 
not been thoroughly studied.  Furthermore, the activities of the purified 
phenolic compounds isolated from maple syrup that may be responsible for 
any observable anti-inflammatory activities have not been reported. 
Inflammation is implicated in multiple chronic human diseases, such as 
cancer, diabetes, cardiovascular and neurodegenerative diseases. 
Overwhelming data suggests that the nuclear factor kappa B (NF-κB) 
signaling pathway is a predominant upstream molecular signaling pathway 
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that causes inflammation through enhanced cytokine, nitric oxide (NO), and 
prostaglandin (PG) production (Guo, Kong, & Meydani, 2009; He & Karin, 
2011; Santangelo, et al., 2007; Vallabhapurapu & Karin, 2009). NF-κB, a 
homo- or hetero-dimeric inducible transcription factor, resides in the cytoplasm 
in an inactive state and when activated, translocates to the nucleus (Valovka & 
Hottiger, 2011). In the nucleus, the activated form of NF-κB induces the 
transcription of genes encoding pro-inflammatory mediators such as 
prostaglandin-E2 (PGE2), NO, and other inflammatory mediators such as 
tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6) in 
response to pathologic stimuli (Park, Lee, Lee, & Kim, 2013). NO and PGE2 
are widely used as anti-inflammatory activity markers for high throughput 
biologically active compound screening (Djoko, Chiou, Shee, & Liu, 2007). 
Both NO and PGs are synthesized by inducible isoforms of the enzymes, nitric 
oxide synthase (NOS) and cyclooxygenases (COX), respectively (Chiu & Lin, 
2008; Korhonen, Lahti, Kankaanranta, & Moilanen, 2005; Posadas, et al., 
2000). Cyclooxygensase-2 (COX-2) and inducible nitric oxide synthase (iNOS) 
have critical roles in the response of tissues to injury or infectious agents. 
These inducible enzymes are essential components of the inflammatory 
response, injury repair, and carcinogenesis (Posadas, et al., 2000; Vane & 
Botting, 1998). The activated form of NF-κB has been found to mediate 
cancer, atherosclerosis, myocardial infarction, diabetes, arthritis, Alzheimer’s 
disease, osteoporosis, and other inflammatory diseases (Kaltschmidt & 
Kaltschmidt, 2009; Morgan & Liu, 2011). Thus, dietary agents that can 
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suppress NF-κB activation, such as plant natural products, including 
phenolics, can potentially prevent, delay the onset, or treat NF-κB mediated 
diseases (Lau, Joseph, McDonald, & Kalt, 2009; Mortensen, et al., 2008; Park, 
et al., 2012; Saracino & Lampe, 2007).  Currently, many well-known dietary 
plant phenolics, such as resveratrol, curcumin, and quercetin, are thought to 
elicit anti-inflammatory and health promoting effects through downregulation of 
the NF-κB signaling pathway in macrophages (Kang, et al., 1999; Kang, Heng, 
Yuan, Baolin, & Fang, 2010; Korhonen, et al., 2005; Rasheed, et al., 2009). 
Moreover, previous research has shown that plant extracts and their purified 
compounds inhibit the pro-inflammatory COX-2 enzyme and the transcription 
factor, NF-κB (Henry, et al., 2009; Rettig, et al., 2008).   
In the present study, we examined the potential for a phenolic-enriched 
maple syrup ethyl acetate extract (MS-EtOAc) to reduce inflammation 
endpoints in lipopolysaccharide (LPS)-stimulated RAW 264.7 murine 
macrophages in vitro. The inflammatory markers, NO and PGE2, along with 
NF-κB activity, were measured. Lastly, 15 individual phenolic compounds 
(structures shown in Fig. 1 and identities shown in Table 1), previously 
isolated from maple syrup by our group (Li & Seeram, 2010, 2011b), were 
evaluated for their effects on NO and PGE2 production in the LPS-stimulated 
macrophages. 
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2.3. Materials and Methods 
2.3.1. Phenolic-enriched maple syrup ethyl acetate extract (MS-EtOAc) 
Maple syrup was donated to our laboratory by the Federation of Maple Maple 
Syrup Producers of Quebec and was extracted with ethyl acetate as 
previously reported (González-Sarrías, Li, & Seeram, 2011). The extract was 
standardized to phenolic content by the Folin–Ciocalteau method as 34% 
gallic acid equivalents as previously reported (González-Sarrías, Li, & 
Seeram, 2011). 
 
2.3.2. Isolation and identification of pure compounds from maple syrup  
The isolation and identification of compounds from maple syrup have been 
previously reported (Li & Seeram, 2010, 2011b). The maple syrup isolates are 
predominantly phenolics belonging to lignan, coumarin, stilbene, and phenolic 
derivative sub-classes. Unfortunately, since many of the compounds were 
isolated in small quantities, and we were limited by sample availability, we 
were only able to pursue studies on 15 of the pure compounds (identities are 
shown in Table 1; chemical structures are shown in Fig. 1). In addition, 
because of limited quantity of these pure samples, we were only able to 
evaluate each sample once (in a 96-well format) but at three different 
concentrations for the bioassays described below. 
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2.3.3. Cell culture and treatment 
RAW 264.7 mouse macrophage cells were obtained from American Type 
Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% v/v fetal bovine 
serum (FBS), penicillin G (100 U/mL), and streptomycin (100 µg/mL) (Sigma-
Aldrich, St. Louis, MO) and maintained at 37 ºC in 5% CO2 humidified air. 
RAW 264.7 cells were seeded (1 x 105 cells/100 µL) in 96-well plates. After 24 
h incubation, RAW 264.7 cells were stimulated with 50 ng/mL LPS (Sigma-
Aldrich, St. Louis, MO), followed by treatment with varying concentrations of 
MS-EtOAc extract  (10, 50 and 100 µg/mL) or pure compounds  (10, 25, 50 
µM) for 24 h. MS-EtOAc extract and the pure compounds were solubilized in 
DMSO by sonication. The final DMSO concentration in the culture medium 
was < 0.3%.  Negative controls were not treated with LPS, MS-EtOAc extract 
or pure compounds. Resveratrol (50 µg/mL) (Sigma-Aldrich, St. Louis, MO) 
was used as a positive control for the assays, as it has been previously 
described to decrease LPS-induced NO and PGE2 induction in RAW 264.7 
cells through NF-κB downregulation (Djoko, et al., 2007; Tsai, Lin-Shiau, & 
Lin, 1999). After 24 h incubation, cell culture supernatants were collected for 
NO and PGE2 measurements. Cell lysates were collected for both gene 
expression and protein expression analyses. For gene expression studies, 
RAW 264.7 cells were seeded in a 24-well plate at 1 × 106 cells/500 µL 
density.  For Western blot analysis, cells were plated in a 6-well plate at 2 × 
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106 cells/mL density.  Cell supernatants and lysates were stored at -80°C until 
use. 
 
2.3.4. Cytotoxicity Assay 
The viability of RAW 264.7 macrophages after 24 h of continuous exposure to 
MS-EtOAc extract (10-100 µg/mL) or the pure compounds (10 - 100 µg/mL), in 
the presence or absence of LPS (50 ng/mL), was determined. The MTS [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-
tetrazolium salt] assay (Promega, Madison, CA) was performed as described 
previously (Li, Henry, & Seeram, 2009) with modifications. Briefly, after 24 h of 
treatment, 20 µL of the MTS reagent in combination with the electron-coupling 
agent, phenazine methosulfate, were added to each reaction well.  The cells 
were incubated at 37°C in a humidified incubator for 2 h and the absorbance 
was measured at 490 nm using a spectrophotometer (SpectraMax M2, 
Molecular Devices Corp, Sunnyvale, CA).  
 
2.3.5. Nitric oxide (NO) activity 
The nitrite levels in the cell culture supernatants were assayed as an indicator 
of NO production, according to the Griess reaction as previously described by 
Legault, Girard-Lalancette et al. (2010).  Briefly, cell culture supernatants were 
incubated (1:1) with modified Griess reagent (Sigma-Aldrich, St. Louis, MO) 
for 20 min at room temperature. The optical densities were measured at 540 
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nm and NO concentration was determined by comparison to a standard curve. 
The assay was performed in triplicate and repeated at least 4 times.  
 
2.3.6. Prostaglandin E2 release 
The Prostaglandin E2 Metabolite (PGE2) assay is based on the conversion of 
all major PGE2 metabolites into a single stable derivative, which is measured 
by using an enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, 
MI). Briefly, the protocol was followed using the manufacturer’s protocol: 
(https://www.caymanchem.com/app/template/Product.vm/catalog/514010) 
whereby cell culture supernatants were used to examine the effects of the test 
compounds on PGE2. The experiment was performed with three individual 
samples per treatment. 
 
2.3.7. RNA isolation and qRT-PCR  
For gene expression studies, RNA was extracted from RAW 264.7 cells after 
24 h treatment with MS-EtOAc.  Briefly, the medium was removed and the 
cells were washed with phosphate buffered saline (PBS). Total RNA was 
isolated with TRIzol (Invitrogen, CA, USA) according to the manufacturer’s 
instructions. The RNA concentration was determined by measuring UV 
absorbance of the sample at 260 nm using a NanoDrop (Wilmington, DE, 
USA).  RNA samples were stored at  -80 °C until use. Total RNA (1 µg) was 
reverse transcribed to cDNA using the Transcriptor Reverse Transcriptase 
cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN). According to 
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the manufacturer’s website (http://www.roche-applied-
science.com/shop/products/transcriptor-high-fidelity-cdna-synthesis-kit), the kit 
contains a Transcriptor High Fidelity Reverse Transcriptase which is a blend of 
a recombinant reverse transcriptase and a proofreading mediating enzyme as 
a key component. Gene expression was measured in qRT-PCR reactions 
using SYBR-green with gene-specific oligonucleotide primers (Life 
Technologies, Grand Island, NY) using LightCycler® 480  (Roche Applied 
Science, Indianapolis, IN). Relative mRNA expression of each gene was 
normalized to the β-actin housekeeping gene. The experiment was performed 
in triplicate. 
 
2.3.8. Western blotting 
To extract protein for Western blot analyses, cells were harvested and washed 
with PBS. The whole cell protein extracts were prepared using RIPA buffer. 
The protein lysates were separated by 10% SDS-PAGE. The proteins were 
transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA) prior 
to blocking for 1 h in Blotto (Santa Cruz biotechnology, Santa Cruz, CA) and 
then incubated with primary antibodies specific to iNOS, COX-2, or β-actin 
(Santa Cruz biotechnology, Santa Cruz, CA) for 2 h. Membranes were washed 
3 times with tris-buffered saline with 0.1% Tween 20 (TBST) and then 
incubated with respective anti-rabbit or anti-mouse secondary antibodies 
conjugated to horseradish peroxidase (Sigma-Aldrich, St. Louis, MO) for  45 
min. Bands were visualized on X-ray films using ECL chemiluminescence 
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detection kit (GE Healthcare, Piscataway, NJ) according to the manufacturer’s 
manual.  
 
2.3.9. Transient transfection and luciferase assay 
LPS-induced NF-κB upregulation accounts for a part of LPS-mediated 
activation of variety of other inflammatory genes.  Hence it is important to 
identify the effects of MS-EtOAc extract on the transcriptional activity of NF-κB 
(Djoko, et al., 2007). To monitor these effects of the MS-EtOAc extract, RAW 
264.7 macrophages were transiently co-transfected with pNF-κB and pRL-
CMV reporter vectors (Promega, Madison, CA) using GenePORTER® 3000 
Transfection Reagent (Genlantis, San Diego, CA) according to the 
manufacturer’s protocol. Briefly, the cells were seeded into 96-well plates (1.2 
× 104 cells/100 µL) in complete medium without antibiotics (DMEM +10%FBS) 
and incubated for 24 h (~50-70% confluency). Cells were then treated with the 
transfection complexes and incubated for 72 h before treatment with MS-
EtOAc extract (10, 50 and 100 µg/mL) for 2 h.  LPS was added after 2 h (1 
µg/mL) for 24h. After 5 h, cells were lysed with 20 µL 1x passive lysis buffer 
and NF-κB activity was measured as relative firefly/renilla luciferase activity 
using a Dual-Luciferase® Reporter Assay System (Promega, Madison, CA) 
with a GloMaxTM 20/20 Luminometer (Promega, Madison, CA) according to 
the manufacturer’s protocol. All samples were tested in quadruplicate. 
Luciferase activity was recorded as relative light units (RLU) and expressed as 
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fold change relative to LPS-treatment control and the assay was performed 
using three biological replicates. 
 
2.3.10. Statistical analysis 
All statistical analyses were carried out using the software program GraphPad 
Prism Version 5.0 (GraphPad Software, La Jolla, CA). Experimental data were 
grouped by one variable and were analyzed by unpaired two-tailed t-test or 
one-way ANOVA followed by a Dunnett's multiple comparison test. A value of 
p < 0.05 was considered significant. 
 
2.4. Results and Discussion 
2.4.1. MS-EtOAc extract inhibit NO production in LPS-stimulated RAW 264.7 
cells 
In order to study the anti-inflammatory activity of maple syrup phenolic-
enriched extract, a well-known inflammatory marker, namely NO, was 
selected. The effects of MS-EtOAc extract on NO production was determined 
by the measurement of nitrite released into the culture supernatants by LPS 
stimulated RAW 264.7 cells using the Griess reagent (Guevara, et al., 1998; 
Legault, et al., 2010). Nitrite levels in unstimulated RAW 264.7 cells were at 
baseline levels (2.8 ± 0.2 µM). However, upon stimulation with LPS, nitrite 
accumulation in the culture supernatant increased ~22-fold to 60.83 ± 2.2 µM. 
Resveratrol, a known inhibitor of NO activity (Djoko, et al., 2007; Wadsworth & 
Koop, 1999), was used as a positive control for comparing the activity of MS-
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EtOAc.  Resveratrol (10 µg/mL) inhibited NO release by 88.67% in LPS-
stimulated RAW 264.7 macrophages. Similar activity was obtained with MS-
EtOAc (Fig. 2a), which significantly reduced nitrite production by 84.9% (at 50 
µg/mL) and 94.3% (at 100 µg/mL) as compared to the nitrite production by 
stimulated macrophages. Thus our results show that MS-EtOAc inhibited 
nitrite production in a concentration-dependent manner in LPS-stimulated 
cells. These findings are in agreement with the previous study where NO 
inhibition in LPS-induced RAW 264.7 macrophages was significantly higher 
with a maple syrup ethyl acetate extract in comparison to that of maple sap 
with a mean of about 75% NO inhibition per 25 µg/mL of extract, which 
corresponds to a portion of 0.18 mL of pure maple syrup (Legault, et al., 
2010). 
 
2.4.2. MS-EtOAc inhibits PGE2 production in LPS-stimulated RAW 264.7 cells 
PGE2 also functions as a mediator of inflammation, which is produced by 
metabolism of arachidonic acid by COX enzymes at inflammatory sites 
(Posadas, et al., 2000). The inhibitory effects of MS-EtOAc extract on PGE2 
levels in LPS-stimulated macrophages were evaluated. As shown in Fig. 2b, 
PGE2 production increased following LPS treatment (14 ± 1.4 ng/mL), 
whereas in the absence of LPS, PGE2 levels were close to baseline or were 
undetectable. PGE2 levels were reduced to 0.8 ng/mL by resveratrol treatment. 
Treatment with 100 µg/mL of MS-EtOAc extract markedly reduced PGE2 
levels 85.2% in LPS-stimulated RAW 264.7 cells, to 2.1 ng/mL. However, 
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lower concentrations of MS-EtOAc extract only reduced PGE2 levels by 
approximately 6% as compared to LPS-induced macrophages.  
Taken together, these results suggest that MS-EtOAc extract is capable 
of reducing NO and PGE2 LPS-induced inflammatory effects in stimulated 
RAW 264.7 macrophages. None of the tested concentrations of extract 
inhibited the growth of RAW 264.7 macrophages (Supplementary Fig. 1). 
Hence, the observed reduction in NO and PGE2 production by the MS-EtOAc 
treatment was not attributed to cytotoxic effects. 
 
2.4.3. Pure maple syrup isolates inhibit NO and PGE2 production in LPS-
stimulated RAW 264.7 cells  
Because MS-EtOAc is a complex mixture of compounds that could 
account for its NO and PGE2 inhibitory effects, we tested 15 of its pure isolates 
for their ability to reduce NO and PGE2 production.  These compounds were 
previously isolated from maple syrup and their structures were elucidated by 
NMR methods (Li & Seeram, 2010, 2011b).  In the MS-EtOAc phenolic-
enriched extract, compound 1 is the only stilbene, whereas compound 5 is the 
only coumarin among the tested samples. Compounds 9, 10, 12, 14 and 15 
were all lignans.  All of the other compounds were phenolic derivatives and are 
briefly categorized as follows: compound 13 contained a C6 unit; compound 11 
contained a C6-C1 unit; compounds 2, 3 and 7 contained a C6-C2 unit and 
compounds 4, 6 and 8 contained a C6-C3 unit.  At the test concentrations, the 
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pure compounds did not exhibit any cytotoxicity in the RAW 264.7 cells (data 
not shown).   
Among all of the pure isolates, the only stilbene, (E)-3,3’-dimethoxy-
4,4’-dihydroxystilbene (compound 1), was the most active compound and 
significantly inhibited NO as well as PGE2 production in a concentration 
dependent manner (Table 1).  At 50 µM, compound 1 decreased the nitrite 
level by 92.5% and PGE2 level by 89.5% in media. These results were similar 
to the effects of the well-known stilbene, resveratrol (50 µM; used as a positive 
control), on the above inflammatory markers (data not shown).  
As shown in Table 1, apart from compound 1, the majority of the other 
pure compounds were not effective in modulating NO production in LPS-
stimulated macrophages. However, compounds 3, 7, and 11 reduced PGE2 
levels in a concentration-dependent manner. At 50 µM concentrations, 
compounds 3, 7 and 11 were the most effective in lowering PGE2 levels with 
95, 72.6, and 55.3% decrease, respectively. Interestingly, in this assay, the 
two most active isolates, compounds 3 and 7, both contained a C6-C2 
structural motif. However, compound 2, which also contained the same C6-C2 
structural motif, did not show any activity against the inflammatory markers.  
Based on structure activity related observations, the active compound 3 
contained two aromatic hydroxyl groups while the inactive compound 2 
contained three aromatic hydroxyls.  Moreover, the active compound 7 only 
contained one aromatic hydroxyl group.  Therefore, it would appear that ≤ two 
aromatic hydroxyls are required for inhibition of PGE2 levels but further studies 
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on a larger number of structurally diverse compounds would be required to 
confirm this. Interestingly, compound 7, protocatechuic acid, has been shown 
to have anti-oxidant, anti-inflammatory and anti-cancer activity in vitro and in 
vivo (Lende, et al., 2011; Nakamura, et al., 2000; Reis, et al., 2010; Robbins, 
2003).    
Our data with compound 11, tyrosol, a well-known constituent of olive 
oil,  was in agreement with a previous study where the reported IC50 value for 
tyrosol for lowering NO level was >100 µM (Choe, et al., 2012). Tyrosol (at 1, 
2 and 4 mM concentrations) has been shown to inhibit iNOS and COX-2 
expression in RAW 264.7 cells stimulated with IFN-γ and gliadin through 
reduction in NF-κB, interferon regulatory factor-1 (IRF-1) and signal transducer 
and activator of transcription-1α (STAT-1α) activity (De Stefano, et al., 2007). 
However, this is the first report to show that tyrosol (at 50 µM test 
concentration) inhibits PGE2 level in RAW 264.7 cells stimulated by LPS.  
Based on the above observations (detailed in Sec. 3.1 - 3.3), our 
findings suggest that the unique combination of phenolic phytochemicals in 
MS-EtOAc extract may be responsible for its anti-inflammatory activity. It is 
possible that these compounds work complementarily, additively, and/or 
synergistically in toto to abate inflammatory processes. Unfortunately, several 
of the previously reported pure compounds from MS-EtOAc were not isolated 
in sufficient quantities to facilitate further biological assaying (Li & Seeram, 
2010, 2011b). Thus, future studies to evaluate the effects of all of the purified 
phenolic compounds from MS-EtOAc are warranted. 
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During transformation of maple sap into syrup, unique phenolic and 
non-phenolic compounds are formed due to the intensive heating process. For 
example, Quebecol, a novel process derived phenolic compound has been 
reported in maple syrup (Li & Seeram, 2011a). It has been demonstrated that 
transformation of maple sap in syrup improves NO inhibition activity. The 
heating process involved in the transformation of maple sap in syrup induces 
oxidation of the phenolics, suggesting its implication in the activity (Legault, et 
al., 2010). Further research is needed to identify these compounds as they 
may contribute to the observed biological effects of maple syrup.  
 
2.4.4. Effect of MS-EtOAc extract on iNOS and COX-2 mRNA and protein 
expression in LPS- stimulated RAW 264.7 murine macrophages 
In macrophages exposed to LPS, iNOS and COX-2 mRNA and protein 
expression are modulated, which ultimately results in overproduction of NO 
and PGE2. In order to assess whether the inhibitory effects of MS-EtOAc 
extract on NO and PGE2 were related to the alteration of iNOS and COX-2 
enzymes, we examined their relative gene and protein expression by qRT-
PCR and western blot analysis, respectively.  iNOS and COX-2 mRNA and 
proteins were barely detectable in un-stimulated cells but were strongly 
expressed in lysates of LPS-stimulated RAW 264.7 cells. Resveratrol 
significantly decreased iNOS mRNA and protein levels at 10 µg/mL, which is 
in agreement with the previous reports wherein gene activation of iNOS was 
inhibited by resveratrol (Tsai, et al., 1999). MS-EtOAc decreased iNOS mRNA 
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expression in a concentration-dependent manner, by 51% and 72%, at 50 and 
100 µg/mL, concentrations, respectively (Fig. 3a). Not surprisingly, MS-EtOAc 
extract also inhibited iNOS protein expression in a concentration-dependent 
manner (Fig. 3b). These results suggest that MS-EtOAc extract likely 
decreases nitrite accumulation through decreased iNOS gene and protein 
expression. 
The acquired data clearly indicates that MS-EtOAc extract did not 
inhibit COX-2 mRNA (Fig. 4a) and protein levels (Fig. 4b) but inhibited PGE2 
production as discussed previously. Since COX-2 gene expression was 
upregulated by MS-EtOAc extract treatment, the inhibitory effects observed in 
regards to decreased PGE2 levels may potentially occur at the translational or 
post-translational levels. The reduced PGE2 levels could be due to the 
inhibition at the enzymatic level by MS-EtOAc treatment. Resveratrol has also 
been shown to have a direct inhibitory effect on PG production by suppressing 
COX-1 and COX-2 enzyme activity in a concentration-dependent manner 
(Jang, et al., 1997; Subbaramaiah, et al., 1998).  
MS-EtOAc demonstrated a similar mechanism of action common to 
non-steroidal anti-inflammatory drugs (NSAIDs) in inhibiting PGE2 production. 
In the previous studies, NSAIDs were reported to upregulate COX-2 
expression in rodents (Davies, Sharkey, Asfaha, Macnaughton, & Wallace, 
1997; Minghetti, Polazzi, Nicolini, Creminon, & Levi, 1997; Pang & Hoult, 
1996). Indomethacin was reported to increase COX-2 protein expression at a 
concentration where it also inhibited NO synthesis and iNOS protein 
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expression in LPS-induced murine macrophages (Pang & Hoult, 1996). 
Similarly, ajoene, a natural product present in garlic, was also reported to 
increase COX-2 gene and protein expression but it inhibited NO, PGE2 release 
and iNOS expression (Dirsch, Kiemer, Wagner, & Vollmar, 1998; Dirsch & 
Vollmar, 2001). In murine macrophages prostaglandins are suggested to act 
as negative feedback regulators of COX-2 expression (Davies, et al., 1997; 
Minghetti, et al., 1997; Pang & Hoult, 1996). Hence, inhibition of prostaglandin 
production may cause upregulation of COX-2 expression as shown in our 
study. 
There is a complex ‘cross-talk’ between the iNOS and COX-2 pathways 
as has been evidenced by numerous studies. There are reports suggesting 
that NO seems to decrease COX-2 expression, however, not all published 
reports are consistent. Inhibitors of nitric oxide synthase activity such as NG-
monomethyl-L-arginine (L-NMMA) have been demonstrated to increase COX-
2 protein expression with decrease in NO production in rodent macrophages 
(Habib, et al., 1997; Patel, Attur, Dave, Abramson, & Amin, 1999; Swierkosz, 
Mitchell, Warner, Botting, & Vane, 1995). Reduced NO levels may contribute 
to the observed increased COX-2 protein and mRNA expression with MS-
EtOAc treatment. Besides this negative regulation of COX-2 expression, other 
potential modes of action could be an effect of MS-EtOAc on COX-2 mRNA 
stability or effects at the transcriptional level. Therefore, further investigation is 
required to explore how MS-EtOAc affects the COX pathway and whether it 
inhibits COX activity at the enzymatic level. 
   
 
61
 
2.4.5. MS-EtOAc extract decreases NF-κB response element-luciferase 
reporter construct activity 
Inflammation is associated with high levels of pro-inflammatory 
mediators like NO and PGE2, which are produced by the inducible isoforms of 
enzymes iNOS and COX-2, respectively (Chung, et al., 2008; Nathan, 1992).  
The transcription factor NF-κB, which regulates the expression of iNOS and 
PGE-2, plays a crucial role in inflammatory and immune responses (Chen, 
Castranova, Shi, & Demers, 1999). Thus, modulating NF-κB activating signals 
is one of the widely used strategies for the treatment of diseases associated 
with inflammation. Hence in order to measure NF-κB transcriptional activity, 
the RAW 264.7 cells were transiently transfected with pNF-κB-luc and pRL-
CMV-renilla and reporter constructs were used to determine the effects of MS-
EtOAc extract on cells challenged with LPS. As expected, LPS treatment 
increased activity of the NF-κB promoter construct by about 20-fold as 
compared to control (Fig. 5). The NF-κB activity was decreased by 
approximately 50% with 10 and 50 µg/mL concentrations of MS-EtOAc.  
Moreover, 100 µg/mL of MS-EtOAc decreased NF-κB reporter construct 
activity by ~ 75% (Fig. 5). The data herein supports the hypothesis that MS-
EtOAc extract may interfere with NF-κB transcriptional activity. LPS-induced 
iNOS gene activation has been linked to LPS-mediated NF-κB activation 
(Lowenstein, et al., 1993). Thus downregulation of iNOS expression by MS-
EtOAc may be through reduced NF-κB transcriptional activity.  
   
 
62
NF-κB is also involved in transcriptional control of IL-1-induced COX-2 
gene expression (Newton, Kuitert, Bergmann, Adcock, & Barnes, 1997). 
However, inflammation involves multiple complex pathways and these 
pathways interfere with each other. Thus, NF-κB is not the only transcription 
factor in LPS-mediated COX-2 gene expression in the mouse macrophages. It 
has been reported previously that NF-κB site is not essential for LPS-mediated 
COX-2 gene expression in RAW 264.7 macrophages (Wadleigh, Reddy, 
Kopp, Ghosh, & Herschman, 2000). This might explain the elevated COX-2 
gene and protein expression. 
 On the basis of current results, we propose that the anti-inflammatory 
effect of maple syrup extract could be attributed to the inhibition of 
inflammatory modulators NO and PGE2 through suppression of NF-κB 
transcription. 
 
2.5. Conclusion 
The current study is the first report to investigate the mechanisms underlying 
the anti-inflammatory activity of a phenolic-enriched maple syrup extract and 
several of its purified constituents. We found that the maple syrup extract and 
its purified compounds significantly inhibited the production of LPS-stimulated 
inflammatory markers NO, PGE2 and iNOS through the direct inhibition of NF-
κB transcriptional activity in RAW 264.7 macrophages. However, the 
upregulation of COX-2 gene and protein levels remain unexplained. Overall, 
the cellular mechanisms underlying these multiple effects may be attributed to 
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the unique combination of pure compounds present in the extract, which 
appear to act in toto. More detailed research is needed to get further insights 
into the exact anti-inflammatory mechanism of the MS-EtOAc extract. 
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2.6. Figure legends 
Fig. 1 Compounds isolated from an ethyl acetate extract of Canadian 
maple syrup (MS-EtOAc). 
 
Fig. 2  Effect of MS-EtOAc extract on NO (a) and PGE2 (b) production in 
LPS-stimulated RAW 264.7 cells.  
The cells were co-incubated with LPS (50 ng/mL) and different concentrations 
of MS-EtOAc extract ranging from 10 -100 µg/mL for 24 h. The supernatants 
were then collected for the measurement of NO and PGE2 production using 
Griess reagent and an EIA kit, respectively. MS-EtOAc extract significantly 
inhibited NO (2a) and PGE2 (2b) levels in LPS-stimulated macrophages. The 
values are expressed as the means ± S.D. of three individual samples. ***P < 
0.001 as compared with the LPS-treated macrophages; significant differences 
between groups were determined using a one-way ANOVA test followed by a 
Dunnett’s multiple comparison test. #P < 0.05 solvent control compared with 
the LPS-treated cells; significant difference was determined using unpaired 
student-t test. 
 
Fig. 3 Effects of MS-EtOAc on iNOS mRNA and protein levels in LPS 
treated macrophages.  
RAW 264.7 cells were co-treated with LPS (50 ng/mL) and various 
concentrations of MS-EtOAc extract (10, 50,100 µg/mL) for 24 h. (3a) iNOS 
mRNA levels were determined as described in Section 2. iNOS mRNA 
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transcript levels were normalized to β-actin expression. MS-EtOAc extract 
inhibited iNOS mRNA expression in a concentration-dependent manner. Data 
are expressed as the means ± S.D. of three different samples. (3b) iNOS and 
housekeeping gene GAPDH expressions were monitored as described in 
Section 2.8. MS-EtOAc extract inhibited iNOS protein expression in a 
concentration dependent manner. ***P < 0.001 as compared with the LPS-
treated group; significant differences between groups were determined using a 
one-way ANOVA test followed by Dunnett’s multiple comparison test. #P < 
0.05 solvent control compared with the LPS-treated cells; significant difference 
was determined using unpaired student-t test.  
 
Fig. 4 Effects of MS-EtOAc on COX-2 mRNA and protein expressions in 
LPS-stimulated RAW264.7 macrophages.  
(4a) RAW 264.7 cells were co-treated with LPS (50 ng/mL) and various 
concentrations of MS-EtOAc extract (10, 50,100 µg/mL) for 24 h. 1 µg of total 
cellular RNA was subjected to RT-PCR followed by SYBR-green quantitative 
real-time PCR. COX-2 mRNA transcript levels were normalized to β-actin 
expression. MS-EtOAc extract increased COX-2 mRNA expression in a 
concentration dependent manner. Data are expressed as the means ± S.D. of 
three different samples. (4b) COX-2 protein expression was measured as 
described in section 2.8. MS-EtOAc extract treatment increased COX-2 
protein expression. ***P < 0.001 as compared with the LPS-treated group; 
significant differences between groups were determined using a one-way 
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ANOVA test followed by Dunnett’s multiple comparison test. #P < 0.05 solvent 
control compared with the LPS-treated cells; significant difference was 
determined using unpaired student-t test. 
 
Fig. 5 Effects of MS-EtOAc on LPS induced NF-κB luciferase activity in 
macrophages.  
RAW 264.7 cells were transiently co-transfected with pNF-κB and pRL-CMV 
reporter vectors. NF-κB activity was measured using a Promega dual 
luciferase assay system. MS-EtOAc significantly reduced the LPS-induced 
increase in NF-κB-dependent luciferase enzyme expression in a 
concentration-dependent manner. Data is the mean ± S.D. of three different 
samples. *P < 0.05, **P < 0.01 and ***P < 0.001 as compared with the LPS-
treated group; significant differences between groups were determined using a 
one-way ANOVA test followed by Dunnett’s multiple comparison test. #P < 
0.05 solvent control compared with the LPS-treated cells; significant difference 
was determined using unpaired student-t test. 
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2.7. Tables 
Table 1: Effect of pure compounds isolated from an ethyl acetate extract of 
Canadian maple syrup (MS-EtOAc) on NO and PGE2 levels in LPS-induced 
RAW 264.7 macrophages.* 
 
 
*The cells were incubated with 50 ng/mL LPS and 10, 25 and 50 µM of pure compounds (1-15). After 24 h, the 
supernatants were collected for determination of NO by Griess reaction and PGE
2
 levels by EIA assay. Data is the 
mean ± S.D. of three different samples.  
 
 
 
 
 
No Name 
% NO 
inhibition 
at 50 µM 
% PGE2 inhibition 
10 
µM 
25 
µM 
50 
µM 
1  (E)-3,3'-Dimethoxy-4,4'-dihydroxystilbene 92.5 30.2 76.5 89.5 
2  3',4',5'-Trihydroxyacetophenone 0 0.0 0 7.5 
3  4-Acetylcatechol 6.5 56.0 88.6 95.0 
4  2,3-Dihydroxy-1-(3,4-dihydroxyphenyl)-1-propanone 1 0.0 0.0 0.0 
5  Isofraxidin 0 0.0 0.0 0.0 
6  2,3-Dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)-1-propanone 0 0.0 0.0 0.0 
7  Tyrosol 1.6 0.0 45.0 72.6 
8  3-Hydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl) propan-1-one 0 0.0 0.0 0.0 
9  Isolariciresinol 1.7 0.0 0.0 0.0 
10  
5-(3'',4''-dimethoxyphenyl)-3-hydroxy-3-(4'-
hydroxy-3'-methoxybenzyl)-4- (hydroxymethyl) 
dihydrofuran-2-one 
0 0.0 2.0 6.2 
11  Protocatechuic acid (3,4-Dihydroxybenzoic acid) 0 13.8 31.5 55.3 
12  Threo-guaiacylglycerol-β-O-4'-dihydroconiferyl alcohol 0 0.0 0.0 0.0 
13  4-Hydroxycatechol (hydroxyhydroquinone) 0 0.0 0.0 0.0 
14  Sakuraresinol 6.4 0.0 5.8 28.1 
15  Syringaresinol 2.2 0.0 7.5 23.8 
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2.8. Figures 
 
 
 
 
 
 
 
Fig. 1 Compounds isolated from an ethyl acetate extract of 
Canadian maple syrup (MS-EtOAc). 
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Fig. 2 Effect of MS-EtOAc extract on NO (a) and PGE2 (b) 
production in LPS-stimulated RAW 264.7 cells. 
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expressions in LPS-stimulated RAW264.7 
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Supplementary Fig. 1 
Effect of MS-EtOAc extract on cell viability in LPS-induced RAW 264.7 
cells. The cells were co-incubated with LPS (50 ng/mL) and different 
concentrations of MS-EtOAc extract ranging from 10-100 µg/mL for 24 h. The 
MTS-PMS reagent (20 µL) was then added and the optical densities were 
measured after 2 h. The values are expressed as the means ± S.D. of three 
individual samples.  
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3.1. Abstract	  
Pure maple syrup is highly regarded as a natural sweetener.  Our laboratory 
has conducted extensive chemical and biological studies characterizing maple 
syrup and we have developed a food grade standardized maple syrup extract 
(named, MSX), which is well tolerated in rats. In this project, firstly we explored 
mechanism involved in hypoglycemic effects of MSX in HepG2 cells. Glucose 
lowering effects of MSX (at 100 µg/mL) was attributed to increased AMPK 
phosphorylation and lowered gluconeogenic gene expression as compared to 
control. Secondly, we also evaluated the anti-lipogenic effect of MSX 
treatment in mature differentiated 3T3-L1 murine adipocytes and human 
visceral adipocytes. MSX treatment (at 50, 100 µg/mL concentrations) to 
mature adipocytes decreased lipid accumulation compared to control in both 
murine and human adipocytes. In 3T3-L1 adipocytes, this effect was 
associated with downregulation of adipo/lipogenic protein expression (e.g. 
PPARγ, SREBP-1). We also observed reduced mRNA expression of the pro-
inflammatory mediators, namely IL-6, and TNF-α. The current study adds to 
the growing body of in vitro and in vivo data supporting the biological effects 
and potential health benefits of the natural sweetener, maple syrup. 	  	  	  	  
Keywords: Maple syrup; Phenolics; 3T3L1; HepG2; AMPK; gluconeogenesis; 
lipogenesis	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receptor γ (PPARγ); CCAAT-enhancer-binding protein (C/EBPα); sterol-
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   84 
3.2. Introduction :	  
In last few decades, the prevalence of type 2 diabetes mellitus (T2DM) has 
radically increased. Insulin resistance (IR) along with hyperglycemia and 
hyperinsulinaemia is the hallmark of T2DM. In T2DM, hyperglycaemia is 
predominantly caused by atypical increase in hepatic gluconeogenesis, 
leading to drastic increase in glucose levels (1, 2). Metformin, a well-known 
anti-diabetic drug, primarily corrects hyperglycaemia and hyperinsulinaemia by 
lowering hepatic gluconeogenesis via 5’ adenosine monophosphate-activated 
kinase (AMPK) activation (3). 	  
There is also an established link between obesity and diabetes due to related 
inflammatory processes (4). Obesity leads to increased circulation of pro-
inflammatory markers leading to ‘metabolic inflammation’ which has been 
linked to the pathogenesis of IR and T2DM in humans and animal models (4). 
The de-lipidating effects of a well-studied polyphenol, resveratrol, via 
peroxisome proliferator-activated receptor γ (PPARγ), CCAAT-enhancer-
binding protein (C/EBPα) and sterol-regulatory element-binding protein 
(SREBP-1) etc., is well established (5). Phenolics have attracted significant 
research attention due to their diverse biological functions and potential 
positive effects on human health (6-8). Plant natural products, especially those 
rich in phenolics, have been shown to exert anti-inflammatory properties and 
therefore may have beneficial effects against diseases with an inflammatory 
component such as diabetes, obesity, cancer, cardiovascular disease, and 
arthritis(9-14).	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Despite the availability of a wide variety of sweeteners, there is increasing 
consumer demand for natural sweeteners among which pure maple syrup is 
highly regarded. Maple syrup has different grades (ranging from light to amber 
to dark, based on light transmittance) and is predominantly used for table 
consumption. Notably, the maple syrup industry generates large volumes of 
dark and ‘off-flavored’ grades of maple syrup, which are not suitable for table 
consumption and are regarded as industrial ‘by-products’. Similar to other food 
industries, for e.g. cranberry extracts being produced from the squeezed fruit 
pulp left over after juice extraction, these maple by-products are viable starting 
materials for the maple syrup industry to use to develop a food grade maple 
syrup-derived botanical extract. Recently, our laboratory has conducted 
extensive chemical and biological studies on a laboratory-scale phenolic-
enriched maple syrup extract. This work led to development of a nutraceutical 
grade maple syrup-derived extract (named, MSX) starting from by-products of 
the industry (15). MSX is chemically standardized and well tolerated by rats 
(non-toxic at doses of up to 1000 mg/kg/day), has a reduced sugar content 
compared to maple syrup (ca. 50% vs. 66%; constituting sucrose and complex 
polysaccharides) and maintains the natural profile of constituents (minerals, 
vitamins, organic acids, amino acids, phytohormones and phytochemicals) 
found in the food. Dietary compounds ‘phenolics’ are predominantly present 
among other phytochemicals in maple syrup extract. Given the beneficial 
health effects of polyhenols, herein we propose that polyphenol-rich MSX with 
unique chemical matrix would exert potential positive biological effects. 	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Our recent published studies have shown that a laboratory scale phenolic-
enriched extract of maple syrup decreases nuclear factor kappa B (NF-κB) 
activity and downstream inflammatory targets in murine macrophages (16). 
Moreover, maple syrup extracts have been shown to have antioxidant (6), α-
glucosidase enzyme inhibitory (17), anticancer (18) and anti-inflammatory (19) 
properties in vitro. In addition, maple syrup has been shown to have liver 
protective effects (20), improve metabolic response (21), and ability to reduce 
plasma glucose level compared to a sucrose solution alone (22, 23) in animal 
models. Recently, St-Pierre et al., (2014) reported that maple syrup produced 
low glycaemic and insulinaemic responses in vivo, and thus represents a 
natural sweetener alternative to refined sugar (21). Recently, our lab has 
reported MSX treatment lowered media glucose levels as compared to control 
in human HepG2 cells (15). However, the mechanism behind hypoglycemic 
effect of MSX is still unknown. Therefore, given all of above published in vitro 
and animal data, we believe that further investigation into demonstrating the 
hypoglycemic and hypolipidemic effects of this novel MSX extract is 
warranted. 	  
In this investigation, we hypothesized that nutraceutical grade MSX extract 
lowered glucose levels via AMPK phosphorylation in hepatocytes. Moreover, 
we postulate the de-lipidating effects of MSX extract by downregulating the 
lipogenic targets in mature adipocytes.	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3.3. Materials and Methods :	  
3.3.1. Chemicals	  
The cell lines HepG2 and 3T3-L1 preadipocytes were purchased from 
American Type Culture Collection (ATCC) (Manassas, VA, USA). Human 
visceral adipocytes and the reagents for maintaining and differentiating them 
were purchased from Lonza biotechnology. Cell culture reagents such as 
Dulbecco's modified Eagle’s medium (DMEM), Hank's balanced salt solution 
(HBSS), fetal bovine serum (FBS) and fetal calf serum (FCS) were obtained 
from Lonza biotechnology. Trypsin-EDTA (ethylenediaminetetraacetic acid) 
and penicillin–streptomycin were bought from Gibco BRL (Gaithersburg, MD, 
USA). Metformin, resveratrol, Oil Red O (ORO), isobutylmethylxanthine 
(IBMX), dimethyl sulfoxide (DMSO), primary antibody anti-β-actin and 
peroxidase-conjugated secondary antibodies were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All primary antibodies were obtained from Cell 
Signaling Technology, Inc. (Beverly, MA, USA) except anti-SREBP1 and anti-
PEPCK antibodies were purchased from Abcam. ECL™ detection reagent 
was bought from GE Healthcare (Buckinghamshire, UK). Glucose assay kit 
was purchased from Eton Bioscience (San Diego, CA, USA). High-capacity 
cDNA reverse transcription kit was from Applied Biosystems (Foster City, CA, 
USA). SYBR Green PCR Master Mix was obtained from Roche Applied 
Science (Indianapolis, IN, USA). Protein assay kit was purchased from Bio-
Rad. Immobilion polyvinylidene difluoride (PVDF) membranes were bought 
from Millipore EMD Corporation (Billerica, MA, USA). Zhang et al. (2014) had 
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previously described the preparation and chemical composition of the maple 
syrup nutraceutical extract (named, MSX), which was used in this study (15). 	  	  
3.3.2. HepG2 Cell culture and treatment	  
HepG2 cells were maintained in a high-glucose (4.5 g/L) DMEM supplemented 
with 10% FBS, 2 mM glutamine, 1000 U/L penicillin and 100 mg/L 
streptomycin at 37 °C, 5% CO2, as described previously (15). The cells were 
seeded into a 12-well plate at a density of 4 x 104 cells/well and cultured for 6-
8 h. The cells were incubated with the low-glucose (1 mg/L) DMEM detection 
media supplemented with 2 mM glutamine and 1% FBS. After overnight 
incubation, the cells were treated with metformin (1 mM) or MSX extract (at 50 
and 100 µg/mL; stock solutions made in DMSO) diluted in the low glucose 
detection medium. The final DMSO concentration was 0.1% (v/v) in the test 
extracts. The cell supernatants and the cell lysates were collected after 24 h 
treatment.	  	  
3.3.3. Adipocyte culture and treatment	  
3T3-L1 preadipocytes were maintained in DMEM containing 10% FCS, 100 
U/mL penicillin and 100 µg/mL streptomycin to confluence at 37°C. The cells 
were seeded in 6-well and 24-well plates Adipocyte differentiation was induced 
at 2 days post-confluence (Day 0), using a mixture of IBMX (0.5  mM), 
dexamethasone (0.25  µM), and insulin (5  µg/mL) in DMEM containing 10% of 
FBS. On day 2, day 4 and day 6, this medium was replaced with DMEM 
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containing 10% of FBS and insulin only. The medium was switched to DMEM 
containing 10% of FBS on day 8 for 24 h. On day 9, the cells were treated with 
MSX extract (at 50 and 100 µg/mL) and after 48 h the cell culture media and 
cell lysates were collected and stored at -80°C until analysis. To put the data 
from our assays into context, other therapeutics know to impact adipocyte 
function were included, such as metformin (4 mM) or resveratrol (50  µM/10 
µg/mL) in these in vitro assays. These concentrations were chosen based 
upon previous studies that have reported the effective concentrations of the 
above-mentioned positive controls in the adipocytes for lowering the lipid 
content (24, 25).	  
Human visceral adipocytes were cultured and differentiated as per the 
manufacturer’s instructions (Lot # 0000313366). Briefly, human primary 
preadipocytes were grown to confluence in Preadipocyte growth medium-2 
provided in 5% CO2 at 37°C. When the cells reached confluence, the medium 
was replaced with Preadipocyte differentiation medium supplemented with a 
cocktail of insulin, dexamethasone, indomethacin and isobutyl-methylxanthine 
to Preadipocyte Growth Medium-2 for 10 days and cells were monitored for 
lipid droplet formation. After 10 days of culture, the adipocyte medium was 
withdrawn and cells were incubated with the MSX extract (100 µg/mL) and 
positive controls. After 24 h, the cell culture media was removed and the cells 
were stained with ORO solution for visualizing lipid droplets.	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3.3.4. Glucose Consumption Assay 	  
The glucose concentration in the HepG2 cell supernatants was determined 
using a glucose assay kit as per the manufacturer’s instructions. Absorbance 
was measured at 490 nm using a spectrophotometer (SpectraMax M2, 
Molecular Devices Corp, Sunnyvale, CA, USA), and the assay was performed 
in triplicates.	  	  
3.3.5. Oil red O staining and quantification	  
During differentiation of pre-adipocytes into adipocytes, intracellular lipid 
droplets are accumulated. ORO dye is used for staining these lipid droplets 
(26, 27). Briefly, after incubation with test extracts for given period of time the 
cells were washed twice with phosphate buffered saline (PBS); followed by 
fixing with 10% formalin for 1 h. The cells were washed twice with PBS and 
stained with filtered ORO solution (150 mg/ 50 mL Oil Red O and 60% (v/v) 
isopropanol in distilled water) for 15 min. The cells were then thoroughly 
washed with distilled water before imaging under an optical microscope at x10 
magnification (EVOS FL Auto, Life technologies, Carlsbad, CA, USA).  
Then the Oil Red O retained in the cells was extracted with isopropanol, the 
absorbance was spectrophotometrically determined at 570  nm using 
SpectraMax M2 (Molecular Devices Corp, Sunnyvale, CA, USA).  
 
3.3.6. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis 
Total RNA was extracted using a Trizol reagent and 1 µg of the extracted RNA 
	   91 
was reverse transcribed into cDNA using a cDNA reverse transcription kit. 
Then the mRNA expression levels were quantified by quantitative real-time 
PCR using SYBR Green PCR Master Mix and the Lightcycler 480 Real Time 
PCR system (Roche Applied Science, Indianapolis, IN) according to the 
manufacturer’s protocol. The quantification of gene expression with real-time 
PCR data was calculated relative to β-actin gene expression. 	  
3.3.7. Western blot	  
The cells were washed once with phosphate-buffered saline and lysed in RIPA 
buffer. Protein concentration was measured using a bichonic protein assay kit. 
Proteins were separated using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto PVDF membranes. After 1 
h incubation in blocking solution (5% skim milk), the membranes were 
incubated overnight with primary antibodies in cold room. The membranes 
were washed thrice with Tris buffered saline/Tween-20 (TBST) for 10 min 
each followed by incubation with horseradish peroxidase-conjugated 
secondary antibodies for 1 h at room temperature. The membranes were 
again washed three times with TBST and then developed on X-ray films using 
ECL™ detection reagent. The bands were quantified using the Image J 
program (NIH, Washington, DC, USA).	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3.3.8. Statistical analyses	  
All statistical analyses were carried out using the software program GraphPad 
Prism Version 5.0 (GraphPad Software, La Jolla, CA, USA). Results are 
expressed as the means ± the standard error of the mean (S.E.). The 
experimental data was analyzed by unpaired one-tailed t-test (for compairing 
differences between two individual groups) or one-way ANOVA (for comparing 
differences between all groups together) followed by a Dunnett's multiple 
comparison test. p < 0.05 was considered significant.	  	  
3.4. Results & Discussion:	  
3.4.1. MSX increase glucose consumption in HepG2 cells by downregulating 
gluconeogenic genes via AMPK activation	  
It has been reported that natural products can regulate glucose and lipid 
metabolism in HepG2 liver hepatocytes (28). Similarly, in our recent MSX 
study (15) in HepG2 cells, MSX lowered glucose levels in the media along with 
clinical anti-diabetic drug metformin, after brief incubation for 7 h. Given that 
MSX decreased glucose levels in HepG2 cells through increased glucose 
consumption, it was investigated whether MSX constituents are activators of 
the AMPK pathway, which suppress gluconeogenesis (29), similar to 
metformin (30). Herein, the treatment was extended further for 24 h in HepG2 
cells as contrast to our recent study in which the cells were treated only for 7 
h. Briefly, HepG2 cells were incubated with low glucose media overnight 
followed by treatment with MSX (50 and 100 µg/mL) or metformin (100 µM or 
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1 mM) for 24 h. The cell culture media was collected for measurement of 
glucose. As shown in Fig. 1, MSX (100 µg/mL) reduced media glucose levels 
to 70% of DMSO treated control cells. Next, the expression of gluconeogenic 
rate limiting enzymes, (e.g. phosphoenolpyruvate carboxykinase [PEPCK] and 
glucose-6-phosphatase [G6pase], was evaluated (31). After 24 hrs MSX (100 
µg/mL) treatment, G6pase mRNA expression was reduced to 68% of control. 
However, PEPCK mRNA expression was similar to vehicle-treated controls 
(Fig. 2). 	  
In order to conduct further investigation into gluconeogenic pathway, upstream 
regulator AMPK protein expression was studied. AMPK activation is commonly 
detected by monitoring its phosphorylation at Thr-172 and phosphorylation of 
downstream target acetyl-CoA carboxylase-1 (ACC-1), using phospho-specific 
antibodies. ACC-1 is a key enzyme involved in fatty acid synthesis, which is 
phosphorylated and inactivated by AMPK (32). MSX (100 µg/mL) slightly 
increased the ratio of pAMPK/ AMPK and pACC-1/ ACC-1 by about 40% and 
26% of control, respectively (Fig. 3). 	  
Moreover, MSX reduced the expression of PEPCK protein to about 55% and 
43% of control at 50 µg/mL and 100 µg/mL concentration, respectively. Thus, 
MSX could be inhibiting PEPCK at translational level (Fig. 3) but not 
transcriptionally (Fig. 2). 	  
Thus, glucose-lowering effect of MSX at higher concentration (100 µg/mL) 
could be attributed to downregulation of G6pase gene expression and PEPCK 
protein expression through AMPK activation. These results supported the 
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published in vivo studies with maple syrup; which reported reduced plasma 
glucose levels compared to a sucrose solution alone in an anti-diabetic animal 
model (22, 23). However, this is a preliminary study and further more detailed 
in vivo studies are needed to support this data.	  	  
3.4.2. MSX imparts lipid-lowering effects in mature mouse and human 
adipocytes  	  
Next, MSX was evaluated for anti-lipogenic effects in mature mouse 3T3-L1 
and human visceral adipocytes. Figs. 4A and 4C depict ORO staining of lipid 
droplets in 3T3-L1 adipocytes and human visceral adipocytes treated with 
DMSO vehicle (0.1%), resveratrol (50 µM), metformin (1- 4 mM), or MSX (50 
and/or 100 µg/mL). Metformin and resveratrol were selected because of 
documented anti-lipogenic activity in both differentiated 3T3-L1 and human 
adipocytes (24, 25, 33). Resveratrol, at the concentration selected, reduced 
the staining to 78% of vehicle-treated control adipocytes (Fig. 4B). In contrast, 
metformin and MSX (50 and 100 µg/mL) decreased the ORO staining by 
approximately 40-50% of control (Fig. 4B). To put our data in context with 
human health perspective, we tested MSX in mature adipocytes from a human 
donor. Metformin and MSX treatment reduced ORO staining in human 
adipocytes to 64% and 43% of vehicle-treated controls, respectively (Fig. 4D).	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3.4.3. MSX downregulated lipogenic targets in mature 3T3-L1 adipocytes.  	  
In metabolic syndrome, adipocytes play crucial role in lipid storage and 
metabolism (34). In adipocytes, several transcription factors act in concert 
during the adipogenesis and lipogensis phase, including PPARγ, C/EBPα, and 
SREBP-1 (34-36). In order to explore the molecular mechanisms involved in 
MSX anti-lipogenic effects, the cell lysates were collected after 48 h treatment 
for evaluating lipogenic target protein expression in mature 3T3-L1 adipocytes. 
Fig. 5 illustrates that MSX downregulated adipo/lipogenic transcription factors 
(i.e. PPARγ, C/EBPα and SREBP-1 protein expression). PPARγ and C/EBPα 
regulate the expression of variety of genes that are involved in different 
pathways including insulin sensitivity (glucose transporter GLUT4), lipogenesis 
(fatty-acid-binding protein, FABP4) and lipolysis (lipoprotein lipase, LPL, 
perilipin) and the secreted factors (adiponectin and leptin) (37).  Here, we 
investigated the effect of MSX treatment on two targets, FABP4 and perilipin, 
in differentiated adipocytes. FABP4 is involved in fatty acid uptake, transport, 
and metabolism (38), whereas perilipin is localized at the periphery of lipid 
droplets and plays a pivotal role in lipid storage (39). MSX treatment 
downregulated the expression of these downstream targets in a concentration 
dependent manner. SREBP-1 induces the expression of lipogenic enzymes, 
including ACC-1 and fatty acid synthase (FAS) (34). MSX decreased protein 
expression of both ACC-1 and FAS in a concentration dependent manner. 
These observations depict decreased protein expression of adipo/lipogenic 
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targets after MSX treatment, which are consistent with reduced lipid staining in 
MSX-treated mature adipocytes depicted in Fig 4. 	  
It is now well accepted that inflammation and associated pro-inflammatory 
processes are centrally linked to several chronic human diseases including 
obesity and diabetes (40). Hence, after exhibiting anti-lipogenic effect, MSX 
also demonstrated specific effects on mature adipocytes that likely contribute 
to its overall anti-inflammatory effects. TNF-α and IL-6 are two key mediators 
of the inflammatory response in mature 3T3-L1 adipocytes that have been 
linked to obesity-related inflammation. Thus, MSX effect on adipocyte 
inflammation was explored by measuring TNF-α and IL-6 mRNA expression 
(Fig. 6).  At 48 hours, resveratrol reduced TNF- α or IL-6 mRNA expression to 
60% and 40% of control respectively. In addition, MSX treatment at 50 µg/mL 
also reduced TNF-α and IL-6 to about 20% of control, however 100 µg/mL 
MSX treatment reduced both inflammatory targets to 36-47%. This is in 
agreement with our previous research where we have exhibited anti-
inflammatory effects of MSX (15) and maple syrup ethyl acetate extract (16) in 
lipopolysaccharide-induced macrophages. Moreover, in this study we have 
demonstrated inhibitory effect of MSX treatment on inflammatory markers in 
mature adipocytes. This is not surprising as MSX contains high levels of 
polyphenols, which are well-known antioxidants and anti-inflammatory agents 
(41). Interestingly, MSX contains stilbenes which are structurally related to 
resveratrol, a well-known polyphenol, thus we could anticipate MSX anti-
lipogenic and anti-inflammatory effects (15). 	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MSX also contains high quantity of phytohormone abscisic acid (ABA), which 
has been proposed to improve insulin sensitivity and obesity-related 
inflammatory diseases through a PPAR γ-dependent mechanism. ABA is 
structurally similar to thiazolidinediones (drugs prescribed for diabetic 
management) (42). Dietary abscisic acid has been reported to improve 
glucose tolerance and obesity-related inflammation in db/db mice fed high-fat 
diet (43). MSX is particularly rich in lignans and these polyphenolic 
compounds are also found in flaxseed. Interestingly, flaxseed lignan have 
been shown to inhibit fat accumulation and induce adiponectin expression in 
high-fat diet-induced mouse model (44).	  
In conclusion, as depicted in Fig. 7 the lowered glucose levels after MSX 
treatment were attributed to AMPK activation in HepG2 hepatoma cell model. 
However, the effect of MSX-treatment were not drastic in HepG2 cells. 
Moreover, we demonstrated delipidating effects of MSX extract treatment by 
downregulating protein expression of adipo/lipogenic transcription factors and 
their downstream targets in differentiated 3T3L1 adipocytes (Fig. 6). In future, 
it would be interesting to explore mechanistic insights into obesity-linked 
inflammatory pathway using MSX-treated human adipose tissue explants.	  
This study, using in vitro models, provided preliminary data necessary to guide 
and support future in vivo studies investigating the potential use of a novel 
food grade maple syrup extract (MSX) as a nutraceutical preparation for 
positive impact on overall health.	  	  
	   98 
Acknowledgement	  
This project was supported by Agriculture and Agri-Food Canada from the 
Developing Innovative Agri-Products (DIAP) program. This work was also 
supported by grants from the National Institute of Health [4R01ES016042, 
5K22ES013782 to ALS] for the supplies. Spectrophotometric data were 
acquired from instruments in the RI-INBRE core facility located at the 
University of Rhode Island (Kingston, RI, USA) supported by grant # 
5P20GM103430-13 from the National Institute of General Medical Sciences of 
the National Institutes of Health. PN was supported by a graduate student 
scholarship from the Omar Magnate Family Foundation.	  	  
Conflict of interest	  
The authors declare no conflicts of interest.	  	  	  	  	  	  	  	  	  	  	  
	   99 
3.5. Figure legends 
Fig. 1. Effect of MSX extract on glucose levels in the media in HepG2 
hepatoma cells. Cells were treated with MSX (50 and 100 µg/mL) or 
metformin (100 µM) in a low glucose media for 24 h and the cell supernatants 
were collected. MSX extracts inhibited glucose levels in the media in a 
concentration-dependent manner. The values are expressed as the means 
±SE of three individual samples. ‘*’ indicates P < 0.05 as compared with the 
control.  
 
Fig. 2. Effect of MSX extract on mRNA expression of genes involved in 
gluconeogenesis, namely G6pase (A) and Pepck (B) in HepG2 hepatoma 
cells. Cells were treated with MSX (50 and 100 µg/mL) or metformin (1 mM) in 
a low glucose media for 24 h and the cell lysates were collected. MSX extracts 
downregulated the gene expression of G6pase (A) and Pepck (B). The values 
are expressed as the means ±SE of three individual samples. ‘*’ indicates P < 
0.05 as compared with the control.  
 
Fig. 3. Effect of MSX extract on protein expression of pAMPK, pACC and 
Pepck in HepG2 hepatoma cells. Cells were treated with MSX (50 and 100 
µg/mL) or metformin (1 mM) in a low glucose media for 24 h and the cell 
lysates were collected. MSX extracts upregulated the expression of pAMPK, 
pACC, and Pepck.	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Fig. 4. Effect of MSX extract on lipid accumulation by ORO staining and 
quantification in mature 3T3-L1 (A,B) and human visceral adipocytes 
(C,D). Cells were treated with MSX (50 and 100 µg/mL) or metformin (1 or 4 
mM) or resveratrol (50 µM) for 48 h and ORO staining was performed to stain 
and quantify lipid droplets in differentiated murine adipocytes (4A & 4B) and in 
mature human visceral adipocytes (4C & 4D). ‘*’ indicates P < 0.05 and ‘**’ 
indicates P < 0.01 as compared with the control.  
 
Fig. 5. Effect of MSX extract on protein expression of lipogenic targets 
after MSX treatment in mature 3T3-L1 cells. Cells were treated with MSX 
(50 and 100 µg/mL) or metformin (1 or 4 mM) or resveratrol (50 µM) for 48 h 
and the cell lysates were collected after 48 h MSX treatment in mature 3T3-L1 
adipocytes for protein expression. MSX extracts downregulated the protein 
expression of adipo/lipogenic targets. 
 
Fig. 6. Effect of MSX extract on gene expression of inflammatory markers 
in mature 3T3-L1 adipocytes. Cells were treated with MSX (50 and 100 
µg/mL) or resveratrol (50 µM) for 48 h and the cell lysates were collected for 
mRNA expression. MSX extracts reduced the expression of inflammatory 
genes TNF-α and IL-6 in differentiated 3T3-L1 cells. The values are expressed 
as the means ±SE of three individual samples. Significant differences between 
groups were determined using a one-way ANOVA test followed by Dunnett’s 
multiple comparison test. ‘*’ indicates P < 0.05 as compared with the control.  
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Fig. 7. MSX hypoglycemic and anti-lipogenic effect in HepG2 cells and 
3T3-L1 cells. 
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3.6. Figures :	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Fig. 1. Effect of MSX extract on glucose levels in the 
media in HepG2 hepatoma cells.  
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Fig. 2. Effect of MSX extract on mRNA expression of 
genes involved in gluconeogenesis, namely G6pase 
(A) and Pepck (B) in HepG2 hepatoma cells. 
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Fig. 3. Effect of MSX extract on protein expression of pAMPK, pACC 
and Pepck in HepG2 hepatoma cells.	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Fig. 4. Effect of MSX extract on lipid accumulation by ORO staining and 
quantification in mature 3T3-L1 (A,B) and human visceral adipocytes 
(C,D).  
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Fig. 5. Effect of MSX extract on protein expression of lipogenic 
targets after MSX treatment in mature 3T3-L1 cells. 
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Fig. 6. Effect of MSX extract on gene expression 
of inflammatory markers in mature 3T3-L1 
adipocytes.  
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Fig. 7. MSX hypoglycemic and anti-lipogenic effect in HepG2 cells 
and 3T3-L1 cells. 
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SUMMARY AND CONCLUSION 
 
1. In this thesis, we have demonstrated that bioactive polyphenol-rich extracts 
namely- Longvida® and food grade maple syrup extract exert positive health 
benefits beyond basic nutrition, thus impacting overall health and wellness. 
2. A novel curcumin formulation Longvida® showed improved solubility over 
unformulated curcumin, and significantly decreased the LPS-induced pro-
inflammatory mediators in macrophages. 
3. Maple syrup extract and its purified compounds significantly inhibited the 
production of inflammatory markers through the direct inhibition of NF-kB 
transcriptional activity in stimulated macrophages. Overall, the cellular 
mechanisms underlying these multiple effects may be attributed to the unique 
combination of pure compounds present in the extract, which appear to act in 
toto. 
4. We demonstrated delipidating effects of food-grade MSX extract treatment 
by downregulating protein expression of adipo/lipogenic transcription factors 
and their downstream targets in differentiated murine 3T3L1 adipocytes. MSX 
treatment also decreased lipid accumulation in human adipocytes. MSX 
extract could also have potential application in obesity-linked inflammation. 
5. In conclusion, this study, using in vitro models, provided preliminary data 
necessary to guide and support future in vivo studies investigating the 
potential use of a novel curcumin formulation Longvida® and food grade 
maple syrup extract (MSX) as a nutraceutical preparation for positive impact 
on overall health.	  
